Oral products containing porous sponges
By using a porous cellulose sponge carrier to encapsulate flavoring agents and active ingredients in capsule form, the problems of low delivery efficiency and insufficient biodegradability of existing oral products are solved, resulting in an oral product with efficient delivery and convenient operation.
Patent Information
- Application Number
- CN202480088252.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-20
- Filing Date
- 2024-12-18
- Publication Date
- 2026-11-17
AI Technical Summary
Existing oral care products suffer from inefficiency and insufficient biodegradability in delivering flavoring agents and active ingredients, and traditional sponge materials are inconvenient to handle in the oral cavity.
Using porous cellulose sponge as a carrier, active ingredients and flavoring agents are encapsulated in capsule form with adhesives, adsorbed or absorbed inside the sponge, and released in the oral cavity by utilizing the porous structure and elastic properties of the sponge.
It improves the delivery efficiency of flavoring agents and active ingredients, enhances biodegradability, and provides a convenient oral handling experience.
Smart Images

Figure CN123124886A_ABST
Abstract
Description
Technical Field
[0001] This disclosure relates to oral products intended for human use. The oral products are configured for oral use and deliver substances such as flavoring agents and / or active ingredients during use. Such products may include tobacco or tobacco-derived products, or may be tobacco-free alternatives. Background Technology
[0002] There are many product categories designed for oral use and enjoyment. For example, oral tobacco products containing nicotine, which is known to have both stimulant and anti-anxiety properties, have been available for many years. Traditional forms of so-called "smokeless" tobacco products include snuff, snus, and chewing tobacco, which are typically made almost entirely of particulate, granular, or fragmented tobacco and are either dispensed by the user or provided to the user in individual portions (such as in single-use pouches or sachets). See, for example, the types, ingredients, and processing methods of smokeless tobacco formulations described in the following patents: U.S. Patent No. 6,668,839 to Williams; U.S. Patent No. 6,834,654 to Williams; U.S. Patent No. 6,953,040 to Atchley et al.; U.S. Patent No. 7,032,601 to Atchley et al.; U.S. Patent No. 7,694,686 to Atchley et al.; U.S. Patent No. 7,810,507 to Dube et al.; U.S. Patent No. 7,819,124 to Strickland et al.; U.S. Patent No. 7,861,728 to Holton, Jr. et al.; U.S. Patent No. 7,901,512 to Quinter et al.; U.S. Patent No. 8,627,828 to Strickland et al.; and U.S. Patent No. 11,246,334 to Atchley, each of which is incorporated herein by reference.
[0003] In addition, traditional tobacco and non-tobacco materials have been combined with other ingredients to form product forms that differ from traditional smokeless products, such as lozenges, tablets, gels, etc. See, for example, the product types described in the following patents: U.S. Patent Application Publication No. 2008 / 0196730, Engstrom et al.; U.S. Patent Application Publication No. 2008 / 0305216, Crawford et al.; U.S. Patent Application Publication No. 2009 / 0293889, Kumar et al.; U.S. Patent Application Publication No. 2010 / 0291245, Gao et al.; U.S. Patent Application Publication No. 2011 / 0139164, Mua et al.; U.S. Patent Application Publication No. 2012 / 0037175, Cantrell et al.; U.S. Patent Application Publication No. 2012 / 0055494, Hunt et al.; U.S. Patent Application Publication No. 2012 / 0138073, Cantrell et al.; U.S. Patent Application Publication No. 2012 / 0138074, Cantrell et al.; U.S. Patent Application Publication No. 2013 / 0074855, Holton, Jr.; Holton, The following U.S. Patent Application Publication No. 2013 / 0074856 by Jr.; U.S. Patent Application Publication No. 2013 / 0152953 by Mua et al.; U.S. Patent Application Publication No. 2013 / 0274296 by Jackson et al.; U.S. Patent Application Publication No. 2015 / 0068545 by Moldovanu et al.; U.S. Patent Application Publication No. 2015 / 0101627 by Marshall et al.; and U.S. Patent Application Publication No. 2015 / 0230515 by Lampe et al. are each incorporated herein by reference.
[0004] There is a growing interest in developing new types of oral products that deliver beneficial sensory or biological activity. These products typically contain flavoring agents and / or active ingredients such as nicotine, caffeine, or botanical materials. In one form, such products are packaged as pouches containing powdered or granular compositions. See, for example, U.S. Patent Application Publication No. 2023 / 0049343 by Keller et al.; U.S. Patent Application Publication No. 2022 / 0071984 by Poole et al.; U.S. Patent Application Publication No. 2021 / 0330590 by Hutchens et al.; U.S. Patent Application Publication No. 2021 / 0186081 by Gerardi et al.; U.S. Patent Application Publication No. 2021 / 0177754 by Keller et al.; U.S. Patent Application Publication No. 2021 / 0177043 by Gerardi et al.; and U.S. Patent Application Publication No. 2021 / 0169867 by Holton, Jr. et al., all of which are incorporated herein by reference.
[0005] Brief Overview
[0006] This invention provides an oral product suitable for oral administration, comprising a porous sponge (e.g., a cellulose sponge) carrying an oral composition that can be released in the oral cavity, the oral composition comprising at least one active ingredient, at least one flavoring agent, or a combination thereof. Using a cellulose sponge as a carrier for the oral composition offers various advantages. For example, using a cellulose sponge can provide an oral product with enhanced biodegradability. Furthermore, the porous cellulose sponge has a large pore volume, providing a very high surface area for receiving the oral composition. Additionally, the cellulose sponge is an inherently elastic material, suitable for manipulation / chewing by the user in the oral cavity. Movement or chewing of the sponge within the oral cavity naturally causes the sponge's pores to contract, which facilitates the release of the oral composition within the oral cavity.
[0007] This disclosure includes, but is not limited to, the following implementation methods.
[0008] Implementation Method 1: An oral product suitable for oral administration, comprising: A porous sponge that carries an oral composition that can be released in the oral cavity.
[0009] Implementation Method 2: The oral product as described in Implementation Method 1, wherein the porous sponge comprises a cellulose material, such as a regenerated cellulose material.
[0010] Embodiment 3: An oral product as described in Embodiment 1 or 2, wherein the oral composition comprises at least one water-soluble component, such as at least one active ingredient, at least one flavoring agent, or a combination thereof.
[0011] Embodiment 4: An oral product as described in any one of Embodiments 1-3, wherein the oral composition comprises one or more active ingredients selected from the group consisting of: nutritional supplements, plant materials, amino acids, vitamins, minerals, terpenes, and combinations thereof.
[0012] Embodiment 5: An oral product as described in any one of Embodiments 1-4, wherein the oral composition comprises a nicotine component selected from nicotine free bases, nicotine salts, nicotine polymer complexes, or combinations thereof.
[0013] Embodiment 6: An oral product as described in any one of Embodiments 1-5, wherein the oral composition comprises nicotine in an amount of about 0.001% to about 10% by weight of the composition, calculated as free base and based on the total weight of the composition.
[0014] Embodiment 7: An oral product as described in any one of Embodiments 1-6, wherein the oral composition comprises one or more flavoring agents, one or more salts, one or more sweeteners, one or more binders, one or more humectants, one or more gums, tobacco materials, or combinations thereof.
[0015] Embodiment 8: An oral product as described in any one of Embodiments 1-7, wherein the oral composition is attached to or absorbed / adsorbed within the porous sponge by an adhesive component.
[0016] Embodiment 9: The oral product as described in Embodiment 8, wherein the adhesive component is selected from povidone, alginate, pectin, gum, carrageenan, pullulan, zein, cellulose ether, starch, dextran, acrylic resin, or a combination thereof.
[0017] Embodiment 10: An oral product as described in any one of Embodiments 1-9, wherein the oral composition is in the form of one or more capsules, the capsules comprising an encapsulating agent encapsulating the at least one active ingredient, at least one flavoring agent, or a combination thereof.
[0018] Implementation method 11: An oral product as described in implementation method 10, wherein one or more capsules comprise a plurality of microcapsules.
[0019] Embodiment 12: An oral product as described in any one of Embodiments 1-11, wherein the oral product exhibits biodegradability according to one or more of ASTM D5338, ASTM D5511, ASTM D5526, D5988, ASTM D6400 and ASTM D6691.
[0020] Embodiment 13: The oral product as described in any one of Embodiments 1-12, wherein the porous sponge is characterized by one or more of the following: i) Density is between approximately 20 and approximately 60 kg / m³ 3 Within the range; ii) Its water absorption capacity is approximately 10 to 20 times the dry weight of a porous sponge; and iii) The pore size ranges from about 4 nm to about 1000 micrometers, for example, from about 1 to about 500 micrometers or from about 1 to about 100 micrometers.
[0021] Implementation Method 14: A method for preparing an oral product, comprising: Provide porous sponges; and A porous sponge is treated with an oral composition that can be released into the oral cavity, the oral composition comprising at least one active ingredient, at least one flavoring agent, or a combination thereof.
[0022] Implementation Method 15: The method as described in Implementation Method 14, wherein the treatment includes spraying the oral composition onto a porous sponge, soaking the porous sponge in the oral composition, or injecting the oral composition into the porous sponge.
[0023] Implementation 16: The method as described in Implementation 14 or 15, wherein the treatment includes treating a porous sponge with a plurality of microcapsules containing an oral composition.
[0024] Implementation 17: The method of implementation 16 further includes treating the multiple microcapsules with an adhesive component before treating the porous sponge with the multiple microcapsules.
[0025] Embodiment 18: The method of any one of Embodiments 14-17 further includes treating the porous sponge with an adhesive composition before treating the porous cellulose sponge with the oral composition.
[0026] Embodiment 19: The method of any one of Embodiments 14-18, wherein the porous sponge comprises a cellulose material, such as a regenerated cellulose material.
[0027] Embodiment 20: An oral product or method as described in any one of Embodiments 1-19, wherein the porous sponge does not dissolve or decompose in the oral cavity, for example, wherein the porous sponge is intended to be removed from the oral cavity after use.
[0028] These and other features, aspects, and advantages of this disclosure will become apparent from the following detailed description of embodiments, taken in conjunction with the accompanying drawings, which are briefly described below. This disclosure includes any combination of two, three, four, or more of the embodiments described above, as well as any combination of two, three, four, or more features or elements shown in this disclosure, whether or not such features or elements are explicitly combined in the detailed description herein. This disclosure is intended to be read holistically, such that any separable feature or element in any of its various aspects and embodiments should be considered as intended to be composable unless the context clearly specifies otherwise. Attached Figure Description
[0029] Having given a general overview of various aspects of this disclosure above, the description will now take place with reference to the accompanying drawings, which are not necessarily drawn to scale. The drawings are merely illustrative and should not be construed as limiting the scope of this disclosure.
[0030] Figure 1 This is a perspective view of an oral product in the form of a cellulose sponge carrying an oral composition according to an exemplary embodiment of the present disclosure; and
[0031] Figure 2 This is a perspective view of an oral product in the form of a cellulose sponge enclosed in a pouch, according to an exemplary embodiment of the present disclosure. Detailed Implementation
[0032] This disclosure will now be described more fully below with reference to exemplary embodiments thereof. These exemplary embodiments are described so that this disclosure will be thorough and complete, and will fully convey the scope of this disclosure to those skilled in the art. In fact, this disclosure may be implemented in many different forms and should not be construed as limited to the embodiments shown herein; rather, these embodiments are provided to enable this disclosure to meet applicable legal requirements.
[0033] As used in this specification and claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly indicates otherwise.
[0034] Oral products containing porous cellulose sponges
[0035] This disclosure relates to a product suitable for use in the oral cavity for delivering, for example, one or more active ingredients and / or flavoring agents into the oral cavity. The oral product includes a porous sponge carrying an oral composition comprising at least one component to be delivered to the oral cavity. As used herein, reference to "porous sponge" refers to a material having a large pore volume, generally capable of absorbing liquids, and exhibiting resilience. Sponges can be constructed from a variety of materials, including cellulose, synthetic polymers such as polyethylene, polyurethane, or Plasazote® cross-linked polyethylene, rubber materials such as EPDM (ethylene propylene diene monomer), PVC / nitrile rubber or neoprene rubber, silicone, etc. For brevity, the remainder of this disclosure focuses on cellulose sponge materials. However, various characteristics and parameters associated with cellulose sponges herein may also be applied to other sponge materials.
[0036] Cellulose sponges can be formed using any method known in the art. In some embodiments, the sponge material comprises regenerated cellulose material. As known in the art, regenerated cellulose can be formed by removing non-cellulose compounds from wood, contacting the extracted wood with caustic soda, and then sequentially contacting it with carbon disulfide and sodium hydroxide to produce a viscous solution. Exemplary methods for preparing regenerated cellulose are provided in U.S. Patent No. 4,237,274 to Leoni et al.; U.S. Patent No. 4,268,666 to Baldini et al.; U.S. Patent No. 4,252,766 to Baldini et al.; U.S. Patent No. 4,388,256 to Ishida et al.; U.S. Patent No. 4,535,028 to Yokogi et al.; U.S. Patent No. 5,441,689 to Laity; U.S. Patent No. 5,997,790 to Vos et al.; and U.S. Patent No. 8,177,938 to Sumnicht, all of which are incorporated herein by reference.
[0037] Regenerated cellulose sponges are typically formed using a mixture of a regenerated cellulose solution as described above, reinforcing fibers such as flax, jute, cotton, regenerated cellulose fibers, and an inorganic pore-forming agent. Typically, this mixture is a viscous solution containing 5 to 8% by weight cellulose, 6 to 100% by weight reinforcing fibers based on the weight of cellulose, and 900 to 2500% by weight inorganic pore-forming agent based on the weight of cellulose. The pore-forming agent is usually composed of sodium sulfate decahydrate crystals or other alkali metal salts with high water of crystallization content, such as sodium acetate trihydrate, sodium carbonate decahydrate, trisodium phosphate dodecahydrate, disodium phosphate dodecahydrate, potassium sodium tartrate tetrahydrate, etc. The final pore size will depend on the size of the pore-forming agent crystals. If desired, colorants, such as dyes or pigments, can also be added to the mixture, or added to the sponge after formation, for example, by spraying the colorant onto the sponge or immersing the sponge in a colorant solution.
[0038] The mixture is then introduced into a desired mold or extruded through orifices of the desired shape and heated to coagulate and regenerate the cellulose solution and melt the pore-forming agent. After regeneration, the molded body is washed with water to remove soluble salts and other components, optionally desulfurized, optionally bleached, and optionally treated with a solution of a plasticizer such as glycerol or propylene glycol. See, for example, WO2010105806 by Hunger et al., U.S. Patent No. 3,276,072 by Politzer et al., and U.S. Patent No. 3,131,076 by Richardson et al., which are incorporated herein by reference. Cellulose sponge materials are commercially available from suppliers such as SPONTEX UK Ltd.
[0039] The shape and size of the sponge can vary without departing from this disclosure. For example, the cellulose sponge can have a circular, rectangular, square, elliptical, triangular, or multi-lobed shape in cross-section. Its size should be suitable for insertion into the oral cavity.
[0040] Cellulose sponges typically have a density in the range of about 20 to about 60 kg / m³. Cellulose sponges generally exhibit high absorbency, with embodiments demonstrating the ability to absorb up to 20 times their dry weight (e.g., about 10 to about 20 times their dry weight). Exemplary pore size ranges include about 4 nm to about 1000 micrometers, for example, about 1 to about 500 micrometers or about 1 to about 100 micrometers.
[0041] In some embodiments, the cellulose sponges (and oral products made therefrom) provided herein are biodegradable and / or compostable. The term "biodegradable" as used with respect to plastic materials refers to polymers that degrade into carbon dioxide / methane, water, and biomass in the presence of bacteria, fungi, algae, and / or other microorganisms under aerobic and / or anaerobic conditions, although materials containing heteroatoms may also produce other products such as ammonia or sulfur dioxide. "Biomass" generally refers to portions of metabolic material that are incorporated into the existing cellular structure of living organisms, or portions that are converted into humic fractions indistinguishable from those of biologically derived materials. "Compostable" means that the material is designed to biodegrade under composting conditions (e.g., at temperatures below those of industrial composting facilities), and "oxidatively degradable" means that the material (typically containing suitable additives) breaks down into microplastics or decomposes through oxidative chemical processes.
[0042] Biodegradability can be evaluated, for example, by the weight loss of the oral product over time. In some embodiments, all biodegradable components achieve 100% biodegradability in time periods of less than 10 years, less than 5 years, less than 2 years, less than 1 year, or less than 6 months under ambient temperature (e.g., 20 °C) and aerobic conditions; it should be understood that these time periods will be shortened upon exposure to elevated temperatures. Certain oral products described herein have been tested to meet the “biodegradable” requirements under the ASTM standards mentioned herein (e.g., according to one or more of ASTM D5338, ASTM D5511, ASTM D5526, ASTM D5988, ASTM D6400, and ASTM D6691), and / or the “easily biodegradable” standard specified in OECD 301B.
[0043] In some embodiments, the cellulose sponges and / or oral products provided herein can be described as substantially (or completely) free of TiO2. “Substantially free” means that no TiO2 has been intentionally added. For example, some embodiments may be characterized as having less than 0.001% by weight of TiO2, or less than 0.0001% by weight, or even 0% by weight of TiO2.
[0044] Cellulose sponges are treated with oral compositions. As used herein, "oral composition" means any composition comprising one or more components suitable for delivery to the oral cavity. Oral compositions may include a variety of components, such as active ingredients, flavoring agents, fillers, binders, humectants, sweeteners, salts, etc. Exemplary oral composition components are described below.
[0045] Oral compositions can be associated with cellulose sponges in a variety of ways. For example, a cellulose sponge can be treated with a powder, solution, or slurry containing an oral composition, such as by soaking the cellulose sponge in an oral composition or by spraying the oral composition onto the sponge. In some embodiments, the oral composition is in the form of one or more capsules (e.g., microcapsules) containing an internal load comprising at least one component (e.g., an active ingredient or flavoring agent) intended for delivery to the oral cavity. The capsules may be contained in a slurry used to treat the cellulose sponge. Alternatively, the oral composition may be added during the formation of the cellulose sponge material, for example, by mixing the oral composition with a viscous cellulose solution prior to the molding step described above. The cellulose sponge carries the oral composition by coating its surface with the sponge surface and by absorbing it into the pores of the sponge.
[0046] In some embodiments, the oral composition is absorbed within and / or adsorbed onto the sponge material, wherein absorption is understood to refer to the process by which the oral composition (typically in liquid form) is drawn into the porous structure of the sponge, and adsorption is understood to refer to the process by which the oral composition accumulates as a surface layer on the sponge material.
[0047] In embodiments where the oral composition is in capsule form, at least one encapsulating agent, typically a polymeric material, will be present. The form of the encapsulated oral composition can vary and typically includes embodiments such as core / shell capsules and an encapsulant containing a polymer matrix having a dispersed phase comprising the oral composition. In some embodiments, the encapsulated oral composition includes a shell or coating incorporating a material such as wax, gelatin, cyclodextrin, hydroxypropyl methylcellulose (“HPMC”), or alginate, and an internal payload containing one or more oral composition components. In this way, multiple encapsulated oral composition units can be incorporated into a cellulose sponge, and the degradation of the shell or coating of the encapsulated oral composition units during product use allows the oral composition to be released within the oral cavity. For example, by using a water-soluble polymer in the construction of the encapsulated oral composition, the encapsulated oral composition can be designed to degrade upon contact with moisture. Alternatively, the encapsulated oral composition can be designed to be physically destroyed by chewing the cellulose sponge in the oral cavity.
[0048] Encapsulated oral composition units used in oral products may be the same or different from each other in size, weight, and shape. A typical encapsulated oral composition unit is spherical. However, suitable encapsulated oral composition units may have other types of shapes, such as generally linear, rectangular, elliptical, or oval. Exemplary encapsulated oral composition units may have a diameter less than about 1,000 micrometers, for example, a diameter ranging from about 1 to about 750 micrometers or from about 10 micrometers to about 500 micrometers. In some embodiments, larger encapsulated oral composition units may be used. For example, the size (diameter) of the encapsulated oral composition unit used may be from about 0.5 mm to about 5 mm or from about 0.6 mm to about 3 mm.
[0049] The total weight of the encapsulated oral composition units contained within the cellulose sponge can vary, but is typically greater than about 0.5 mg, typically greater than about 1 mg, and may be greater than about 5 mg. The total weight of the encapsulated oral composition units is typically less than about 50 mg, typically less than about 250 mg, and may be less than about 10 mg.
[0050] The relative weight of the oral composition units encapsulated in an oral product can vary. Based on the total weight of the oral product, an exemplary weight range is from about 0.1% to about 10%, typically from about 0.2% to about 5%.
[0051] The encapsulated oral composition units can be formed using any encapsulation technique known in the art, for example. For instance, capsules can be formed using various chemical encapsulation techniques, such as solvent evaporation, solvent extraction, organic phase separation, interfacial polymerization, mono- and poly-condensation, in-situ polymerization, liposome encapsulation, and nano-encapsulation. Alternatively, physical encapsulation methods can be used, such as injection molding, spheroidization, granulation, extrusion, microfluidics, spraying, pan coating, fluidized bed coating, annular jet coating, rotary disc atomization, spray cooling, spray drying, spray chilling, fixed nozzle co-extrusion, centrifugal head co-extrusion, or immersion nozzle co-extrusion.
[0052] Coagulation is a colloidal phenomenon that begins with a solution of colloids in a suitable solvent. Depending on the properties of the colloid, various changes will lead to a decrease in its solubility. Due to this decrease, a large portion of the colloid can separate into new phases, thus forming a two-phase system, one with a high colloid concentration and the other with a low colloid concentration. The dispersed colloidal-rich phase manifests as amorphous droplets called coagulated droplets. Upon standing, these coagulate into a transparent, homogeneous, colloidal-rich liquid layer called the coagulated layer, which can be deposited to create the wall material for encapsulating pH adjusters.
[0053] Simple coagulation can be achieved by mixing two colloidal dispersions, one of which has a high affinity for water, or by adding a strongly hydrophilic substance such as an alcohol or sodium sulfate. Water-soluble polymers are concentrated in water by the presence of a non-solvent that is miscible with water but does not dissolve the polymeric phase (such as gelatin). Ethanol, acetone, dioxane, isopropanol, and propanol are exemplary solvents that can induce the separation of coagulated products (such as gelatin, polyvinyl alcohol, or carboxymethyl cellulose). Phase separation can be achieved by adding an electrolyte, such as an inorganic salt, to an aqueous solution of the polymer, such as gelatin, polyvinyl alcohol, or carboxymethyl cellulose.
[0054] In a system of two dispersed hydrophilic colloids with opposite charges, complex aggregation can be induced. The total positive charge on one colloid is neutralized by the negative charge on the other colloid, thereby separating a polymer-rich complex aggregated phase. The gelatin-gum arabic (gum arabic) system is a known example of such a complex aggregation system.
[0055] Organic phase separation is sometimes more simply referred to as "water-in-oil" encapsulation. In this case, the polar core is dispersed in an oily or non-polar continuous medium. The wall material is then dissolved in this continuous medium.
[0056] Regardless of the encapsulation method used, the outer wall or matrix material and / or coating material and solvent used to form the encapsulated oral composition unit of this disclosure can vary. Commonly used material categories for wall / shell or coating materials include proteins, polysaccharides, starches, waxes, fats, natural and synthetic polymers, and resins. Exemplary materials used in the encapsulation process for forming the encapsulated oral composition unit include gelatin, gum arabic, polyvinyl acetate, potassium alginate, carob gum, potassium citrate, carrageenan, potassium polymetaphosphate, citric acid, potassium tripolyphosphate, dextrin, polyvinyl alcohol, povidone, dimethyl polysiloxane, mannitol, dimethyl silicone, refined paraffin wax, ethyl cellulose, bleached shellac, maltodextrin, modified food starch, sodium alginate, guar gum, sodium carboxymethyl cellulose, hydroxypropyl cellulose, sodium citrate, hydroxypropyl methyl cellulose, sodium ferrocyanide, sodium polyphosphate, locust bean gum, methyl cellulose, sodium trimetaphosphate, methyl ethyl cellulose, sodium tripolyphosphate, microcrystalline wax, tannic acid, petroleum wax, terpene resin, astragalus gum, polyethylene, xanthan gum, and polyethylene glycol.
[0057] Encapsulation methods are described, for example, in Gutcho's "Microcapsules and Microcapsule Technology" (1976); Gutcho, "Advances in Microcapsules and Other Capsules Since 1975" (1979); Kondo, "Microcapsule Processing and Technology" (1979); Iwamoto et al., AAPSPharm. Sci. Tech. 2002 3(3): Article 25; McGlumphy's U.S. Patent No. 3,550,598; Tateno et al.'s U.S. Patent No. 4,889,144; Cherukuri et al.'s U.S. Patent No. 5,004,595; Bonner's U.S. Patent No. 5,690,990; Wampler et al.'s U.S. Patent No. 5,759,599; Soper et al.'s U.S. Patent No. 6,039,901; Soper et al.'s U.S. Patent No. 6,045,835; Lew's U.S. Patent No. 6,056,992; Soper et al.'s U.S. Patent No. 6,106,875; T U.S. Patent No. 6,117,455 to Akada et al.; U.S. Patent No. 6,325,859 to DeRoos et al.; U.S. Patent No. 6,482,433 to DeRoos et al.; U.S. Patent No. 6,612,429 to Dennen; and U.S. Patent No. 6,929,814 to Bouwmeesters et al.; U.S. Patent Application Publication No. 2006 / 0174901 to Karles et al. and U.S. Patent Application Publication No. 2007 / 0095357 to Besso et al.; and PCTWO 2007 / 037962 to Holton et al.; each of which is incorporated herein by reference. Exemplary types of commercially available packaging technologies include those marketed under the trade names ULTRASEAL™ and PERMASEAL™, available from Givaudan AB in Vergne, Switzerland.
[0058] To enhance the adhesion / fixation of the oral composition within a cellulose sponge, in some embodiments, an adhesive component may be added to the oral composition. The adhesive component can be any suitable component that increases the tackiness of the oral composition or otherwise enhances its affinity for the cellulose sponge surface. The adhesive component can be, for example, the adhesives described herein. In some cases, certain components of the oral composition provide tackiness without the need for additional adhesive components, such as nicotine resins described herein. Exemplary adhesive components include bioadhesives, such as starch or natural resins, and synthetic resins, such as polyacrylates. When the oral composition is in capsule form, the adhesive component can be applied as an outer coating to the capsule before treating the cellulose sponge with the capsule. In some embodiments, the cellulose sponge is first treated with the adhesive component and then treated with the oral composition. In this way, the oral composition can adhere to the sponge material, meaning that the oral composition either contains at least one component that enhances the tackiness of the composition, thereby enabling the composition to adhere to the sponge material, or the adhesive material is applied separately to the sponge material to enhance the adhesion of the oral composition to the sponge material.
[0059] Some embodiments of this disclosure may be referred to. Figure 1 The description illustrates an embodiment of oral product 100. Oral product 100 includes a cellulose sponge 102 containing an oral composition 104, which may be in the form of multiple capsules.
[0060] The composition within the cellulose sponge
[0061] The oral composition within the cellulose sponge can vary, but will generally include at least one active ingredient and / or at least one flavoring agent. The oral compositions disclosed herein can generally be prepared, for example, by dry mixing of dry ingredients (e.g., fillers, active ingredients, salts, buffers, flavoring agents, etc.) and combining the dry mixture with any liquid ingredient (e.g., a humectant). As described above, the oral compositions can be used in encapsulated form. Exemplary compositional components are provided below.
[0062] The way the various components of the composition are combined can vary. For example, the overall composition containing powdered components may be relatively homogeneous in nature. The components, which may be in liquid or dry solid form, can be mixed in a pretreatment step before being mixed with any remaining components of the composition, or simply mixed with all other liquid or dry ingredients. In some embodiments, the liquid flavoring agent is combined with a porous particulate carrier (e.g., microcrystalline cellulose) to form a dry flavoring agent mixture. This dry flavoring agent can then be combined with other components of the composition (e.g., soluble fillers, active ingredients, etc.). Introducing the flavoring agent in this way may benefit the provision of a more homogeneous product and avoid clumping that can occur due to mixing the liquid flavoring agent with other dry materials. Such clumping is undesirable because it reduces product homogeneity and requires further processing, such as resting time and grinding. In some embodiments, the flavoring agent is added to the other components in a dry form (e.g., spray-dried powder).
[0063] The various components of a composition can be contacted, combined, or mixed together using any mixing technique or apparatus known in the art. Any mixing method that brings the components of the composition into close contact can be used, such as a mixing device with an impeller or other agitating structure. Examples of mixing apparatus include feed drums, conditioning cylinders or conditioning rollers, liquid spray devices, cone mixers, belt mixers, mixers supplied by Littleford Day, Inc. in models FKM130, FKM600, FKM1200, FKM2000, and FKM3000, plowshare mixing drums, Hobart brand mixers, etc. See also the types of methods described in, for example, U.S. Patent No. 4,148,325 to Solomon et al., U.S. Patent No. 6,510,855 to Korte et al., and U.S. Patent No. 6,834,654 to Williams, each of which is incorporated herein by reference. The manner and methods of formulating the compositions will be apparent to those skilled in the art. See, for example, the types of methods shown in, U.S. Patent No. 4,148,325 to Solomon et al.; U.S. Patent No. 6,510,855 to Korte et al.; U.S. Patent No. 6,834,654 to Williams; U.S. Patent No. 4,725,440 to Ridgway et al.; and U.S. Patent No. 6,077,524 to Bolder et al., all of which are incorporated herein by reference.
[0064] filler components
[0065] According to this disclosure, the compositions provided herein may include one or more filler components. Such particulate filler components can achieve a variety of functions, such as enhancing certain sensory properties of the product (such as texture and mouthfeel), enhancing the cohesiveness or compressibility of the product, etc.
[0066] Typically, filler components are porous, granular materials and are cellulose-based. Suitable granular filler components, for example, are any non-tobacco plant material or its derivatives, including cellulose materials derived from such sources. Examples of cellulose-based non-tobacco plant materials include cereals (e.g., corn, oats, barley, rye, buckwheat, etc.), sugar beets (e.g., FIBREX® brand fillers available from International Fiber Corporation), bran fiber, citrus fiber (e.g., CITRI-FI® brand fiber available from Fiberstar), and mixtures thereof. Non-limiting examples of non-tobacco plant material derivatives include starches (e.g., from potatoes, wheat, rice, corn), natural cellulose, and modified cellulose materials. Other examples of potential granular filler components include maltodextrin, dextrose, calcium carbonate, calcium phosphate, lactose, mannitol, xylitol, and sorbitol. Combinations of fillers may also be used.
[0067] As used herein, “starch” can refer to pure starch, modified starch, or starch derivatives from any source. Starch is generally found in granular form in almost all green plants and in various types of plant tissues and organs, such as seeds, leaves, rhizomes, roots, tubers, buds, fruits, grains, and stems. The composition of starch, as well as the shape and size of its granules, can vary. Typically, starches from different sources have different chemical and physical properties. Specific starches can be selected for addition to mixtures based on their ability to impart specific sensory properties to a composition. Starches derived from a wide variety of sources can be used. For example, major sources of starch include cereals (such as rice, wheat, and corn) and root vegetables (such as potatoes and cassava). Other examples of starch sources include acorns, arrowroot, Peruvian carrots (arracacha), bananas, barley, legumes (e.g., broad beans, lentils, mung beans, peas, chickpeas), breadfruit, buckwheat, canna lilies, chestnuts, taro, katakuri, kudzu root, malanga, millet, oats, tuberous yams (oca), konjac (Polynesian arrowroot), sago, sorghum, sweet potatoes, quinoa, rye, cassava (tapioca), taro, tobacco, water chestnuts, and yams. Some starches are modified starches. Modified starches undergo one or more structural modifications, typically aimed at altering their high-temperature properties. Some starches have been developed through genetic engineering and are considered "genetically modified" starches. Other starches are first obtained and subsequently modified through physical (e.g., heating, cold water swelling, etc.), chemical, or enzymatic methods. For example, modified starch can be starch that has undergone chemical reactions, such as esterification, etherification, oxidation, depolymerization (thinning) via acid catalysis or oxidation in the presence of a base, bleaching, transglycosylation and depolymerization (e.g., dextrinization in the presence of a catalyst), crosslinking, acetylation, hydroxypropylation, and / or partial hydrolysis. Enzymatic treatments include contacting natural starch isolates or concentrates, microbial enzymes, and / or enzymes naturally present in plant materials, such as amylases found in corn kernels for modifying corn starch. Other starches are modified by heat treatment, such as pregelatinization, dextrinization, and / or cold water swelling processes. Certain modified starches include monosaccharide phosphates, distarch glycerides, distarch phosphates esterified with sodium trimetaphosphate, phosphorylated distarch phosphates, acetylated distarch phosphates, acetate starch esterified with acetic anhydride, acetate starch esterified with vinyl acetate, acetylated distarch adipate, acetylated distarch glycerides, hydroxypropyl starch, hydroxypropyl distarch glycerides, and sodium octenyl succinate starch.
[0068] In some embodiments, the particulate filler component is a cellulose material or a cellulose derivative, and in some embodiments may include microcrystalline cellulose (“MCC”). The MCC may be synthetic or semi-synthetic, or may be entirely derived from natural cellulose. The MCC may be selected from the group consisting of: AVICEL® grades PH-100, PH-102, PH-103, PH-105, PH-112, PH-113, PH-200, PH-300, PH-302, VIVACEL® grades 101, 102, 12, 20, and EMOCEL® grades 50M and 90M, and mixtures thereof.
[0069] In some embodiments, the particulate filler may be characterized as substantially spherical, such as cellulose spheres. "Substantially spherical" means that at least a portion of the particulate filler component is spherical and / or "globose." Therefore, "substantially spherical" includes slightly elongated (e.g., elliptical) shapes, slightly flattened shapes, etc. Substantially spherical particulate filler components are intended to be distinguished from conventional particulate filler components (e.g., commercially available "fillers" or "particulate fillers" not explicitly designed to be "spherical"). Such conventional particulate filler components typically comprise particles with fairly irregular shapes. In some cases, at least some (e.g., including most) of such conventional particulate filler components include one or more edges (e.g., serrated edges) that are typically not observable in substantially spherical particulate filler components used in the context of this disclosure. Furthermore, the particle shape and size uniformity of substantially spherical filler components is generally much greater than that of conventional particulate filler components.
[0070] In some embodiments, the substantially spherical filler component comprises MCC. In some embodiments, the substantially spherical filler component comprises solid (though porous) MCC spheres. In some embodiments, the substantially spherical filler component comprises hollow MCC spheres. In some embodiments, the center / core of such hollow MCC spheres is not filled; in other embodiments, the center / core of such hollow MCC spheres may be filled with one or more additional components (e.g., flavoring agents, fillers, active ingredients, etc.). Examples of suitable MCC spheres include, but are not limited to, Vivapur® MCC spheres from JRSPharma, with available particle sizes such as 100-200 μm (Vivapur® 100), 200-355 μm (Vivapur® 200), 355-500 μm (Vivapur® 350), 500-710 μm (Vivapur® 500), 710-1000 μm (Vivapur® 700), and 1000-1400 μm (Vivapur® 1000). Further examples of suitable MCC spheres include, but are not limited to, Celphere™ MCC spheres from Asahi Kasei Corporation, such as commercially available MCC spheres with particle sizes of 75-212 μm (Celphere™ SCP-100), 106-212 μm (Celphere™ CP-102), 150-300 μm (Celphere™ CP-203), 300-500 μm (Celphere™ CP-305), and 500-710 μm (Celphere™ CP-507).
[0071] The amount of filler can vary, but based on the total weight of the composition, the filler content typically does not exceed about 75%. Typical ranges for fillers (e.g., microcrystalline cellulose (MCC)) in the composition can be from about 5% to about 70% of the total weight of the composition, for example, about 5%, about 10%, about 15%, or about 20% to about 30%, about 35%, about 45%, or about 60% by weight (e.g., about 5% to about 60% by weight or about 10% to about 45% by weight).
[0072] In some embodiments, the filler further comprises a cellulose derivative or a combination of such derivatives. In some embodiments, the mixture comprises about 1% to about 10% by weight of the cellulose derivative based on the total weight of the composition, with some embodiments comprising about 1% to about 5% by weight of the cellulose derivative. In some embodiments, the cellulose derivative is a cellulose ether (including carboxyl ethers), referring to a cellulose polymer in which one or more hydroxyl groups in the cellulose structure are substituted with alkyl, hydroxyalkyl, or aryl groups. Non-limiting examples of such cellulose derivatives include methylcellulose, hydroxypropylcellulose (“HPC”), hydroxypropyl methylcellulose (“HPMC”), hydroxyethylcellulose, and carboxymethylcellulose (“CMC”). In one embodiment, the cellulose derivative is one or more of methylcellulose, HPC, HPMC, hydroxyethylcellulose, and CMC. In some embodiments, the cellulose derivative is HPC. In some embodiments, the composition comprises about 0% to about 5% by weight of HPC, for example, about 1% to about 3% by weight of HPC, based on the total weight of the composition.
[0073] Water / Moisture Content
[0074] Prior to consumer use of the product, the water content and volatile content of the compositions described herein may vary depending on desired properties. Typically, as present in the product and before insertion into the user's mouth, the water content in the mixture is less than about 60% by weight based on the total weight of the composition, and is generally from about 1% by weight to about 60% by weight, for example, from about 5% by weight to about 55% by weight, from about 10% by weight to about 50% by weight, from about 20% by weight to about 45% by weight, or from about 25% by weight to about 40% by weight, including amounts of at least about 5% by weight, at least about 10% by weight, at least about 15% by weight, and at least about 20% by weight. In some embodiments, the water content of the oral composition is relatively low based on the total weight of the oral composition, for example, from about 1% by weight to about 12% by weight, such as less than about 10% by weight, less than about 8% by weight, less than about 7% by weight, less than about 6% by weight, less than about 5% by weight, or less than about 4% by weight.
[0075] adhesives
[0076] The composition uses an adhesive (or combination of adhesives) in an amount sufficient to provide the desired physical properties and physical integrity. The adhesive material can increase the cohesiveness of the composition and can also act as a gelling agent. Typically, the amount of adhesive present is up to about 50% by weight based on the total weight of the composition, and some embodiments are characterized by an adhesive content of at least about 5% by weight. In some embodiments, the adhesive is present in an amount ranging from about 5% by weight to about 50% by weight based on the total weight of the composition, such as about 5%, about 10%, about 15%, about 20%, about 25%, or about 30% by weight to about 35%, about 40%, or about 45% by weight based on the total weight of the composition.
[0077] Typical adhesives can be organic, inorganic, or combinations thereof. Representative adhesives include povidone, sodium alginate, pectin, gum, carrageenan, pullulan, zein, cellulose derivatives, and combinations thereof. In some embodiments, combinations or blends of two or more adhesive materials may be used. Other examples of adhesive materials are described, for example, in U.S. Patent No. 5,101,839 to Jakob et al.; and U.S. Patent No. 4,924,887 to Raker et al., the entire contents of which are incorporated herein by reference.
[0078] In some embodiments, the adhesive is selected from the group consisting of agar, alginate, carrageenan and other seaweed hydrocolloids, exudate hydrocolloids, cellulose ethers, starch, gum, dextran, povidone, pullulan, zein, or combinations thereof.
[0079] In some embodiments, the binder is a cellulose ether (including carboxyl ethers), referring to a cellulose polymer in which one or more hydroxyl groups in the cellulose structure are replaced by alkyl, hydroxyalkyl, or aryl groups. Non-limiting examples of such cellulose derivatives include methylcellulose, hydroxypropylcellulose (“HPC”), hydroxypropyl methylcellulose (“HPMC”), hydroxyethylcellulose, and carboxymethylcellulose (“CMC”). Suitable cellulose ethers include hydroxypropylcellulose, such as Klucel H from Aqualon; hydroxypropyl methylcellulose, such as Methocel K4MS from DuPont; hydroxyethylcellulose, such as Natrosol 250 MRCS from Aqualon; methylcellulose, such as Methocel A4M, K4M, and E15 from DuPont; and sodium carboxymethylcellulose, such as CMC 7HF, CMC 7LF, and CMC 7H4F from Aqualon. In some embodiments, the binder is one or more cellulose ethers (e.g., a single cellulose ether or a combination of several cellulose ethers, such as two or three). In some embodiments, the adhesive is a cellulose ether selected from the group consisting of methylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, and combinations thereof.
[0080] wind Flavoring
[0081] In some embodiments, the oral composition includes one or more flavoring agents. As used herein, a "flavoring agent" or "flavoring agent" is any substance having a flavor or aroma that is capable of altering the sensory properties associated with an oral product. Examples of sensory properties that can be altered by a flavoring agent include taste, mouthfeel, moisture, cool / warm sensation, and / or aroma / fragrance. Flavoring agents can be natural or synthetic, and the flavor characteristics imparted therefrom can be described as, but are not limited to, fresh, sweet, herbal, candy, floral, fruity, or spicy.
[0082] Specific types of flavors include, but are not limited to, vanilla, coffee, chocolate / cocoa, cream, mint, spearmint, menthol, peppermint, wintergreen, eucalyptus, lavender, cardamom, nutmeg, cinnamon, clove, cascarella, sandalwood, honey, jasmine, ginger, fennel, sage, licorice, lemon, orange, apple, peach, lime, cherry, strawberry, trigeminal nerve stimulants, melatonin, terpenes, and any combination thereof. See, for example, Leffingwell et al., Tobacco Flavoring for Smoking Products, RJ Reynolds Tobacco Company (1972), which is incorporated herein by reference. Flavoring agents may also include components considered as humectants, cooling agents, or smoothing agents, such as eucalyptus or menthol. These flavors may be provided in pure form (i.e., alone) or in a complex form and may be used as concentrates or flavor formulations (e.g., spearmint and menthol, orange and cinnamon; lime, pineapple, etc.). Representative types of components are also shown in U.S. Patent No. 5,387,416 to White et al.; U.S. Patent Application Publication No. 2005 / 0244521 to Strickland et al.; and PCT Application Publication No. WO 05 / 041699 to Quinter et al., each of which is incorporated herein by reference. In some cases, flavoring agents may be provided in spray-dried or liquid form.
[0083] The flavoring agent typically comprises at least one volatile flavor component. As used herein, "volatile" means a chemical substance that readily vaporizes at ambient temperature (i.e., a chemical substance having a high vapor pressure relative to a non-volatile substance at a given temperature). Typically, the volatile flavor component has a molecular weight of less than about 400 Da and typically comprises at least one carbon-carbon double bond, carbon-oxygen double bond, or both. In some embodiments, the at least one volatile flavor component comprises one or more alcohols, aldehydes, aromatic hydrocarbons, ketones, esters, terpenes, terpenoids, or combinations thereof. Non-limiting examples of aldehydes include vanillin, ethyl vanillin, p-anisaldehyde, hexanal, furfural, isovaleraldehyde, cuminaldehyde, benzaldehyde, and citronellol. Non-limiting examples of ketones include 1-hydroxy-2-propanone and 2-hydroxy-3-methyl-2-cyclopenten-1-one. Non-limiting examples of esters include allyl hexanoate, ethyl heptaate, ethyl hexanoate, isoamyl acetate, and 3-methylbutyl acetate. Non-limiting examples of terpenes include sabinene, limonene, γ-terpinene, β-farnesene, nerolidol, thujone, myrcene, geraniol, nerol, citronellol, linalool, and eucalyptol. In one embodiment, the at least one volatile flavor component comprises one or more of ethyl vanillin, cinnamaldehyde, sabinene, limonene, γ-terpinene, β-farnesene, or citral. In one embodiment, the at least one volatile flavor component comprises ethyl vanillin. In another embodiment, the at least one volatile flavor component comprises menthol.
[0084] In some cases, flavoring agents may be provided in spray-dried or liquid form. In some embodiments, liquid flavoring agents are loaded in or on a porous particulate carrier (e.g., adsorbed or absorbed therein or on it) and then combined with other compositional components. Embodiments having flavoring agents present in a dry form (e.g., in or on microcrystalline cellulose) may be advantageous in providing a more uniform product.
[0085] In oral compositions, the amount of flavoring agent present can vary, but is typically up to about 10% by weight based on the total weight of the oral composition, and some embodiments are characterized by a flavoring agent content of at least about 0.1% by weight based on the total weight of the oral composition, such as about 0.1% to about 1% by weight, 0.5% to about 10% by weight, about 1% to about 6% by weight, or about 2% to about 5% by weight. The amount of flavoring agent present in the composition can vary over time (e.g., during storage after the composition is prepared). For example, certain volatile components present in the mixture may evaporate or undergo chemical transformation, resulting in a decrease in the concentration of one or more volatile flavor components.
[0086] Flavor modifiers
[0087] To improve the sensory properties of compositions as disclosed herein, the compositions may include one or more flavor modifiers (“flavor modifiers”) that can mask, alter, block, or enhance the flavor of compositions as described herein. Non-limiting examples of such flavor modifiers include herbs, spices, and flavoring agents with analgesic or anesthetic effects that produce a cooling (e.g., menthol, eucalyptus, peppermint), warming (e.g., cinnamon), or aching (e.g., capsaicin) sensation. Some flavor modifiers fall into more than one overlapping category.
[0088] In some embodiments, the flavor modifier modulates one or more of bitterness, sweetness, saltiness, or sourness. In some embodiments, the flavor modifier targets pain receptors. In some embodiments, the composition comprises an active ingredient having a bitter taste, and a flavor modifier that masks or blocks the perception of the bitter taste. In some embodiments, the flavor modifier is a substance that targets pain receptors (e.g., vanilloid receptors) in the user's oral cavity to mask the bitterness of, for example, another component (e.g., the active ingredient). In some embodiments, the flavor modifier is capsaicin.
[0089] In some embodiments, the taste modifier is the amino acid γ-aminobutyric acid (GABA), which has been mentioned in the section on amino acids above. Studies in mice have shown that, in addition to synaptic inhibition, GABA can also perform one or more functions in taste buds. See, for example, Dvoryanchikov et al., J Neurosci. 2011 Apr 13;31(15):5782-91. Not wishing to be confined to theory, GABA can inhibit the perception of certain tastes, such as bitterness. In some embodiments, the composition comprises caffeine and GABA.
[0090] In some embodiments, the flavor modifier is adenosine monophosphate (AMP). AMP is a naturally occurring nucleotide that can block bitterness or enhance sweetness in food. It does not directly alter bitterness, but it can change the human perception of "bitterness" by blocking relevant receptors.
[0091] In some embodiments, the flavor modifier is Lactisole. Lactisole is an antagonist of sweet taste receptors. Temporarily blocking sweet taste receptors can highlight, for example, umami characteristics.
[0092] When present, the representative amount of the flavor modifier is about 0.01% by weight or more, about 0.1% by weight or more, or about 1.0% by weight or more, but typically less than about 10% by weight of the total weight of the composition (e.g., about 0.01%, about 0.05%, about 0.1%, or about 0.5% to about 1%, about 5%, or about 10% by weight of the total weight of the composition).
[0093] Salt
[0094] In some embodiments, the oral composition may further comprise a salt (e.g., an alkali metal salt), typically used in an amount sufficient to provide the desired sensory properties to the mixture. Non-limiting examples of suitable salts include sodium chloride, potassium chloride, ammonium chloride, calcium chloride, powdered salts, etc. When present, representative amounts of the salt are about 0.25% by weight or more, about 1.0% by weight or more, or about 1.5% by weight or more, but typically constitute about 10% or less, about 7.5% or less, or about 5% or less (e.g., about 0.5% to about 5% by weight) of the total weight of the composition.
[0095] sweeteners
[0096] The composition typically further comprises one or more sweeteners. The sweetener can be any sweetener or combination of sweeteners, and can be a natural sweetener, an artificial sweetener, or a combination of a natural sweetener and an artificial sweetener. Examples of natural sweeteners include isomaltulose, fructose, sucrose, glucose, maltose, mannose, galactose, lactose, stevia, honey, etc. Examples of artificial sweeteners include sucralose, maltodextrin, saccharin, aspartame, acesulfame potassium, neotame, etc. In some embodiments, the sweetener comprises one or more sugar alcohols. Sugar alcohols are polyols derived from monosaccharides or disaccharides through partial or complete hydrogenation. Sugar alcohols have, for example, from about 4 to about 20 carbon atoms, and include erythritol, arabinitol, ribitol, isomaltulitol, maltitol, eurythritol, idotitol, mannitol, xylitol, lactitol, sorbitol, and combinations thereof (e.g., hydrogenated starch hydrolysate). In some embodiments, the mixtures provided herein may comprise a combination of sugar alcohols (e.g., xylitol or erythritol) and a small amount of an artificial or non-nutritive sweetener (e.g., sucralose, aspartame, acesulfame potassium, or any combination thereof). When present, the representative amount of the sweetener may be from about 0.1% by weight to about 20% by weight or more based on the total weight of the composition, for example, from about 0.1% by weight to about 1% by weight, about 1% by weight to about 5% by weight, about 5% by weight to about 10% by weight, or about 10% by weight to about 20% by weight based on the total weight of the composition.
[0097] Moisturizer
[0098] In some embodiments, one or more humectants may be used in the composition. Examples of humectants include, but are not limited to, polyols such as glycerin, propylene glycol, etc. When a humectant is included, it is typically provided in an amount sufficient to provide the desired moisture properties to the composition. When present, the humectant will typically constitute about 20% or less of the composition by weight, or 15% or less of the composition by weight (e.g., about 1% to about 20% by weight, or about 5% to about 15% by weight).
[0099] Processing aids
[0100] If downstream processing of the composition (such as bagging) requires it, a flow aid may also be added to the composition to enhance its flowability. Exemplary flow aids include microcrystalline cellulose, silica, polyethylene glycol, stearic acid, calcium stearate, magnesium stearate, zinc stearate, sodium stearate fumarate, carnauba wax, and combinations thereof. In some embodiments, the flow aid is sodium stearate fumarate. When present, a representative amount of the flow aid may be at least about 0.5% by weight or at least about 1% by weight of the total dry weight of the composition. The amount of flow aid in the composition typically does not exceed about 5% by weight of the total weight of the composition, and often does not exceed about 3% by weight.
[0101] buffer
[0102] In some embodiments, the compositions of this disclosure may include pH adjusters or buffers. Examples of usable pH adjusters and buffers include, but are not limited to, metal hydroxides (e.g., alkali metal hydroxides, such as sodium hydroxide and potassium hydroxide), and other alkali metal buffers, such as metal carbonates (e.g., potassium carbonate or sodium carbonate), or metal bicarbonates, such as sodium bicarbonate. Non-limiting examples of suitable buffers include alkali metal acetates, glycine salts, phosphates, glycerophosphates, citrates, carbonates, bicarbonates, borates, or mixtures thereof. Where present, the buffer or pH adjuster is typically present in an amount of less than about 5% based on the weight of the composition, for example, from about 0.1 wt% to about 1 wt%, from about 0.1 wt% to about 0.5 wt%, or from 0.5 wt% to about 5 wt% based on the total weight of the composition, such as, for example, from about 0.75 wt% to about 4 wt%, from about 0.75 wt% to about 3 wt%, or from about 1 wt% to about 2 wt%.
[0103] In some embodiments, at least one pH adjuster is added to the composition to further enhance the stability of the volatile flavoring agents or active ingredients contained therein. For example, sufficient pH adjuster may be added to the composition to maintain the pH level below 7, such as from about 4 to about 7.
[0104] Colorant
[0105] Colorants may optionally be used in an amount sufficient to provide the desired physical properties to the composition. Examples of colorants include various dyes and pigments, such as caramel color and titanium dioxide. The amount of colorant used in the composition may vary, but when present, it is typically up to about 3% by weight, such as about 0.1% by weight, about 0.5% by weight, or about 1% by weight to about 3% by weight, based on the total weight of the composition.
[0106] Active ingredients
[0107] Typically, the composition comprises one or more active ingredients. As used herein, “active ingredient” means one or more substances belonging to any of the following categories: APIs (active pharmaceutical ingredients), food additives, natural medicines, and naturally occurring substances that can have an effect on the human body. Exemplary active ingredients include any component known to affect one or more biological functions in the body, such as components that provide pharmacological activity or other direct effects in the diagnosis, cure, relief, treatment, or prevention of a disease, or components that affect any structure or function of the human body (e.g., providing stimulation to the central nervous system, having an energizing effect, antipyretic or analgesic effects, or producing other beneficial effects on the body). In some embodiments, the active ingredient may belong to the type commonly referred to as dietary supplements, nutritional supplements, “phytochemicals,” or “functional foods.” These types of additives are sometimes defined in the art as encompassing substances that are generally available from naturally occurring sources (e.g., plant materials) that provide one or more beneficial biological effects (e.g., promoting health, preventing disease, or other medicinal properties) but are not classified or regulated as drugs.
[0108] Non-limiting examples of active ingredients include those belonging to the categories of plant-based ingredients, amino acids, nicotine components and / or pharmaceutical, nutritional and medicinal ingredients (e.g., vitamins such as A, B3, B6, B12, and C). Each of these categories is further described below. The specific selection of active ingredients will vary depending on the desired flavor, texture, and properties of the particular product.
[0109] In some embodiments, the active ingredient is selected from the group consisting of caffeine, taurine, GABA, theanine, vitamin C, lemon balm extract, ginseng, citicoline, sunflower lecithin, and combinations thereof. For example, the active ingredient may include a combination of caffeine, theanine, and optionally ginseng. In some embodiments, the active ingredient includes a combination of theanine, γ-aminobutyric acid (GABA), and lemon balm extract. In some embodiments, the active ingredient includes theanine, theanine, and tryptophan, or theanine and one or more B vitamins (e.g., vitamin B6 or B12). In some embodiments, the active ingredient includes a combination of vitamin C, caffeine, and taurine.
[0110] The specific percentage of active ingredients present will vary depending on the desired properties of the particular product. Typically, the active ingredient or combination thereof is present at a total concentration of at least about 0.001% by weight of the composition, such as in the range of about 0.001% by weight to about 20% by weight. In some embodiments, the active ingredient or combination of active ingredients is present at a concentration of about 0.1% w / w to about 10% by weight, such as, for example, about 0.5% w / w to about 10% by weight, about 1% by about 10% by weight, or about 1% by about 5% by weight, based on the total weight of the composition. In some embodiments, the active ingredient or combination of active ingredients is present at a concentration of about 0.001 wt%, about 0.01 wt%, about 0.1 wt%, or about 1 wt% up to about 20 wt% based on the total weight of the composition, such as, for example, about 0.001 wt%, about 0.002 wt%, about 0.003 wt%, about 0.004 wt%, about 0.005 wt%, about 0.006 wt%, about 0.007 wt%, about 0.008 wt%, about 0.009 wt%, about 0.01 wt%, about 0.02 wt%, about 0.03 wt%, about 0.04 wt%, about 0.05 wt%, about 0.06 wt%. About 0.07 wt%, about 0.08 wt%, about 0.09 wt%, about 0.1 wt%, about 0.2 wt%, about 0.3 wt%, about 0.4 wt%, about 0.5 wt%, about 0.6 wt%, about 0.7 wt%, about 0.8 wt% or about 0.9 wt% to about 1 wt%, about 2 wt%, about 3 wt%, about 4 wt%, about 5 wt%, about 6 wt%, about 7 wt%, about 8 wt%, about 9 wt%, about 10 wt%, about 11 wt%, about 12 wt%, about 13 wt%, about 14 wt%, about 15 wt%, about 16 wt%, about 17 wt%, about 18 wt%, about 19 wt% or about 20 wt%. Further suitable ranges for specific active ingredients are provided below.
[0111] plant materials
[0112] In some embodiments, the active ingredient includes plant components. As used herein, the terms "plant component" or "plant-based" refer to any plant material or fungal-derived material, including plant materials in their natural form and plant materials derived from natural plant materials, such as extracts or isolates from plant materials, or processed plant materials (e.g., plant materials subjected to heat treatment, fermentation, bleaching, or other treatment processes that alter the physical and / or chemical properties of the material). For the purposes of this disclosure, "plant-based" includes, but is not limited to, "herbal materials," which refers to seed-producing plants (e.g., tea or herbal tea) that do not develop durable lignin and are generally valued for their medicinal or sensory properties. Referring to plant materials as "non-tobacco" is intended to exclude tobacco materials (i.e., excluding any plants of the genus *Nicotiana*). In some embodiments, the compositions disclosed herein may be characterized by being free of any tobacco materials (e.g., any embodiment disclosed herein may be completely or substantially free of any tobacco materials). "Substantially free" means that no tobacco materials have been intentionally added. For example, some implementations may have the feature of containing less than 0.001% by weight of tobacco, or less than 0.0001% by weight of tobacco, or even 0% by weight of tobacco.
[0113] When present, the typical concentration of plant material is from about 0.01% w / w to about 10% by weight, such as, for example, based on the total weight of the composition, from about 0.01% w / w, about 0.05% by weight, about 0.1% by weight, or about 0.5% by weight to about 1% by weight, about 2% by weight, about 3% by weight, about 4% by weight, about 5% by weight, about 6% by weight, about 7% by weight, about 8% by weight, about 9% by weight, or about 10% by weight, about 11% by weight, about 12% by weight, about 13% by weight, about 14% by weight, or about 15% by weight.
[0114] The plant materials useful in this disclosure may include, but are not limited to, any compounds and sources shown herein, including mixtures thereof. Certain plant materials of this type are sometimes referred to as dietary supplements, nutritional supplements, “phytochemicals”, or “functional foods.” Certain plant materials are used in traditional herbal medicine in the form of plant-based materials or extracts thereof, and are further described herein. Non-limiting examples of plant materials or plant-derived materials include acai berry (… Euterpe oleracea martius Acerola cherry ( Malpighia glabra ), alfalfa, allspice, angelica root, fennel seeds (e.g., anise), annatto seeds, apples ( Malus domestica Almond oil, Ashwagandha, and false purslane ( Bacopa monniera ), baobab tree, basil ( Ocimum basilicum ), bay leaves, lemon balm, beetroot, bergamot, blackberry (black mulberry) Morus nigraBlack cohosh, black pepper, black tea, blueberries, Paul's ( )), black cohosh, black pepper, black tea, blueberries, Paul's ( ) Peumus boldus Borage, ground ivy, cocoa, calamus root, camu camu ( Myrcaria dubia Caraway seeds, cardamom, blackcurrant, catnip, cattuba, chili pepper, purslane ( Centella asiatica ), Chaga mushroom, Bupleurum chinense, Chamomile, Cherry, Sage, Chives, Chlorophyll, Chocolate, Coriander, Cinnamon ( Cinnamomum cassia ), lemongrass ( Cymbopogon citratus ), citrus, Southern European tanshinone, cloves, coconut ( Cocos nucifera ), coffee, comfrey leaves and roots, cordyceps, coriander seeds, cranberry, cumin, curcumin, damiana, dandelion, taro leaves (Lousang) Dorstenia arifolia ), Xiang Liusang ( Dorstenia odorata ), Echinacea, elderberry, elderflower, dill ( Anethum graveolens Evening primrose, eucalyptus, fennel, daisy, flax, goldenrod ( Galphimia glauca ), garlic, ginger ( Zingiber officinale Ginkgo, ginseng, goji berries, goldenseal, grape seed, grapefruit, rose grapefruit ( Citrus paradisi ), Soursop ( Annona muricata ), green tea, guarana, centella asiatica, hawthorn, hazelnut, hibiscus ( Hibiscus sabdariffa Honeybush, hops, gynostemma pentaphyllum, jamb ( Spilanthes oleraceae ), Jasmine Jasminum officinale ), juniper berries Juniperus communis ), Kaempferia galanga (Thai ginseng), Kava, Laurel, Lavender, Lemon ( Citrus limon ), lemon balm, lemongrass, licorice, clove, lion's mane mushroom, lutein, maca ( Lepidium meyenii Nutmeg peel, marjoram, matcha, milk thistle, mint, mulberry, nard ( Nardostachys chinensis Nutmeg, olives, oolong tea, oranges Citrus sinensis Oregano, papaya, chili powder, menthol, peppermint ( Mentha piperita Allspice, potato peel, primrose, quercetin, quince, red clover, resveratrol, gastrodia ( Rhizoma gastrodiae Rhodiola rosea, rooibos tea (red or green), rosehip ( Rosa canina ), rosemary, saffron, sage, St. John's wort, sandalwood, rooibos tea ( Salvia officinalis ), peppermint, saw palmetto Twisted Pine Tree (Sceletium tortuosum) Schisandra chinensis, Milk thistle (Silybum marianum), Scutellaria baicalensis, Spikenard, Spirulina, Elm bark, High-tannin sorghum bran, High-tannin sorghum rice, Spearmint ( Mentha spicataSpirulina, star anise, astragalus root bran, tarragon, thyme, herbal tea, turmeric, damiana ( Turnera aphrodisiaca Bearberry, valerian, herbs, and violets. Viola odorata) White mulberry, wild yam root, wintergreen, withania somnifera, yaconroot, wrinkled sorrel, yerba mate, and yerba santa.
[0115] In some embodiments, the active ingredient includes lemon balm. Lemon balm ( Melissa officinalis Lemon balm is a herb with a mild lemon scent, belonging to the same family as mint (Lamiaceae). This herb is native to Europe, North Africa, and West Asia. Lemon balm tea, as well as its essential oil and extracts, are used in traditional and alternative medicine. In some embodiments, the active ingredient includes lemon balm extract. In some embodiments, the lemon balm extract is present in an amount of about 1% to about 4% by weight based on the total weight of the composition.
[0116] In some embodiments, the active ingredient includes ginseng. Ginseng is ginseng (… Panax The roots of plants in the genus *Ginsenosides* are characterized by containing unique steroidal saponin phytochemicals (ginsenosides) and gintonin. Ginseng is used as a dietary supplement in energy drinks or herbal teas and is applied in traditional medicine. Cultivated varieties include Korean ginseng (*Ginseng var. kanran*). P. ginseng ), South China ginseng ( P. notoginseng ) and American ginseng ( P. quinquefolius American ginseng and Korean ginseng differ in the types and amounts of ginsenosides present. In some embodiments, the ginseng is American ginseng or Korean ginseng. In some embodiments, the active ingredient includes Korean ginseng. In some embodiments, ginseng is present in an amount of about 0.4% to about 0.6% by weight based on the total weight of the composition.
[0117] For example, certain plant materials (guarana, tea, coffee, cocoa, etc.) may have stimulating effects due to the presence of, for example, caffeine or related alkaloids. Caffeine, for instance, can be obtained by extraction and purification from plant sources (e.g., tea). In some embodiments, the active ingredient includes caffeine. In some embodiments, the caffeine is present in an encapsulated form. An example of encapsulated caffeine is Vitashure®, available from Balchem Corporation (52 Sunrise Park Road, New Hampton, NY 10958).
[0118] When present, caffeine, theophylline, and combinations thereof are typically present at concentrations from about 0.1% w / w to about 15% by weight based on the total weight of the composition, such as, for example, about 0.1% w / w, about 0.2% by weight, about 0.3% by weight, about 0.4% by weight, about 0.5% by weight, about 0.6% by weight, about 0.7% by weight, about 0.8% by weight, or about 0.9% by weight to about 1% by weight, about 2% by weight, about 3% by weight, about 4% by weight, about 5% by weight, about 6% by weight, about 7% by weight, about 8% by weight, about 9% by weight, about 10% by weight, about 11% by weight, about 12% by weight, about 13% by weight, about 14% by weight, or about 15% by weight. In some embodiments, the composition comprises caffeine in an amount from about 1.5% by weight to about 6% by weight based on the total weight of the composition.
[0119] amino acids
[0120] In some embodiments, the active ingredient comprises amino acids. As used herein, the term "amino acid" refers to an organic compound containing amine (-NH2) and carboxyl (-COOH) or sulfonic acid (SO3H) functional groups, as well as the side chain (R group) characteristic of each amino acid. Amino acids can be protein amino acids or non-protein amino acids. "Protein (amino acid)" means that the amino acid is one of the twenty naturally occurring amino acids found in proteins. Protein amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. "Non-protein amino acid" means that the amino acid is either not naturally present in proteins or is not directly produced by cellular mechanisms (e.g., it is a product of post-translational modification). Non-limiting examples of non-protein amino acids include γ-aminobutyric acid (GABA), taurine (2-aminoethanesulfonic acid), theanine (L-γ-glutamylethylamine), hydroxyproline, and β-alanine. In some embodiments, the active ingredient includes theanine. In some embodiments, the active ingredient includes GABA. In some embodiments, the active ingredient includes a combination of theanine and GABA. In some embodiments, the active ingredient is a combination of theanine, GABA, and lemon balm. In some embodiments, the active ingredient is a combination of caffeine, theanine, and ginseng. In some embodiments, the active ingredient includes taurine. In some embodiments, the active ingredient is a combination of caffeine and taurine.
[0121] When present, the concentration of amino acids or combinations of amino acids (e.g., theanine, GABA, and combinations thereof) is typically from about 0.1% w / w to about 15% by weight based on the total weight of the composition, such as, for example, about 0.1% w / w, about 0.2% by weight, about 0.3% by weight, about 0.4% by weight, about 0.5% by weight, about 0.6% by weight, about 0.7% by weight, about 0.8% by weight, or about 0.9% by weight to about 1% by weight, about 2% by weight, about 3% by weight, about 4% by weight, about 5% by weight, about 6% by weight, about 7% by weight, about 8% by weight, about 9% by weight, about 10% by weight, about 11% by weight, about 12% by weight, about 13% by weight, about 14% by weight, or about 15% by weight.
[0122] Vitamins and minerals
[0123] In some embodiments, the active ingredient comprises a vitamin or a combination of vitamins. As used herein, the term "vitamin" refers to an organic molecule (or related group of molecules) of an essential micronutrient required for the normal functioning of metabolism in mammals. Human metabolism requires thirteen vitamins: vitamin A (such as all-trans retinol, all-trans retinol esters, and all-trans β-carotene and other provitamin A carotenoids), vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B7 (biotin), vitamin B9 (folic acid or folate), vitamin B12 (cobalamin derivatives), vitamin C (ascorbic acid), vitamin D (calciferol derivatives), vitamin E (tocopherols and tocotrienols), and vitamin K (quinones). In some embodiments, the active ingredient comprises vitamin C. In some embodiments, the active ingredient is a combination of vitamin C, caffeine, and taurine. In some embodiments, the active ingredient comprises one or more of vitamins B6 and B12. In some embodiments, the active ingredient includes theanine and one or more of vitamins B6 and B12.
[0124] In some embodiments, the active ingredient includes vitamin A. In some embodiments, the vitamin A is encapsulated. In some embodiments, the vitamin is vitamin B6, vitamin B12, vitamin E, vitamin C, or a combination thereof.
[0125] In some embodiments, the active ingredient comprises minerals. As used herein, the term "mineral" refers to inorganic molecules (or related groups of molecules) that are essential micronutrients required for the proper functioning of various systems in a mammalian body. Non-limiting examples of minerals include iron, zinc, copper, selenium, chromium, cobalt, manganese, calcium, phosphorus, sulfur, magnesium, etc. In some embodiments, the active ingredient comprises iron. Suitable sources of iron include, but are not limited to, ferrous salts, such as ferrous sulfate and ferrous gluconate. In some embodiments, the iron is encapsulated.
[0126] When present, the vitamin or mineral (or combination thereof, such as vitamin B6, vitamin B12, vitamin E, vitamin C, or combination thereof) is typically present in concentrations of about 0.01% w / w to about 6% by weight based on the total weight of the composition, such as, for example, about 0.01% w / w, about 0.02% w / w, about 0.03% w / w, about 0.04% w / w, about 0.05% w / w, about 0.06% w / w, about 0.07% w / w, about 0.08% w / w, about 0.09% w / w, or about 0.1% w / w to about 0.2% w / w, about 0.3% w / w, about 0.4% w / w, about 0.5% w / w, about 0.6% w / w, about 0.7% w / w, about 0.8% w / w, about 0.9% w / w, about 1% w / w, about 2% w / w, about 3% w / w, about 4% w / w, about 5% w / w, or about 6% w / w.
[0127] antioxidants
[0128] In some embodiments, the active ingredient includes one or more antioxidants. As used herein, the term "antioxidant" refers to a substance that prevents or inhibits oxidation by terminating free radical reactions and can delay or prevent certain types of cell damage. Antioxidants can be naturally occurring or synthetic. Naturally occurring antioxidants include those found in foods and plant materials. Non-limiting examples of antioxidants include certain plant materials, vitamins, polyphenols, and phenol derivatives.
[0129] Examples of plant materials associated with antioxidant properties include, but are not limited to, acai berry, alfalfa, allspice, annatto seed, apricot oil, basil, propolis, wild bergamot, black pepper, blueberry, borage seed oil, bugleweed, cocoa, calamus root, catnip, cattuba, cayenne pepper, birch polypore, chervil, cinnamon, dark chocolate, potato peel, grape seed, ginseng, ginkgo, St. John's wort, saw palmetto, green tea, black tea, and black cohosh. Cohosh, Cayenne pepper, Chamomile, Clove, Cocoa powder, Cranberry, Dandelion, Grapefruit, Honey tea, Echinacea, Garlic, Evening primrose, White chrysanthemum, Ginger, Goldenseal, Hawthorn, Hibiscus, Gynostemma pentaphyllum, Kava, Lavender, Licorice, Marjoram, Milk thistle, Peppermint, Oolong tea, Beetroot, Orange, Oregano, Papaya, Pennyroyal, Peppermint, Red clover, Rooibos tea (red or green), Rosehip, Rosemary, Sage, Clary sage, Peppermint, Spirulina, Smooth elm bark, Sorghum bran (high tannins), Sorghum grain (high tannins), Tocopheryl bran, Lithospermum leaves and roots, Goji berries, Centella asiatica Kola, thyme, turmeric, bearberry, valerian, wild yam root, wintergreen, yacon root, wrinkled sorrel, yerba mate, yerba mate, false purslane, withaniasomnifera, lion's mane, and milk thistle. These plant materials can be provided fresh, dried, or as essential oils, or as extracts. The plant materials (and their extracts) typically contain a variety of compounds known to provide antioxidant effects, such as minerals, vitamins, isoflavones, phytosterols, allyl sulfides, dithiothiophenes, isothiocyanates, indoles, lignans, flavonoids, polyphenols, and carotenoids. Examples of compounds present in plant extracts or oils include ascorbic acid, peanut endocarotene, resveratrol, sulforaphane, beta-carotene, lycopene, lutein, coenzyme Q, carnitine, quercetin, kaempferol, etc. See, for example, Santhosh et al., Phytomedicine, 12(2005) 216-220, which is incorporated herein by reference.
[0130] Other suitable antioxidants, without limitation, include citric acid, vitamin E or derivatives thereof, tocopherol, epicatechin, epigallocatechin, epigallocatechin gallate, isoascorbic acid, sodium isoascorbate, 4-hexylresorcinol, theaflavins, theaflavins monogallate A or B, theaflavins digallate, phenolic acids, glycosides, quercetin, isoquercetin, hyperoside, polyphenols, catechins, resveratrol, oleuropein, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), tert-butylhydroquinone (TBHQ), and combinations thereof.
[0131] When present, the antioxidant is typically present at a concentration of about 0.001% w / w to about 10% by weight based on the total weight of the mixture / composition, such as, for example, about 0.001% w / w, about 0.005% w / w, about 0.01% w / w, about 0.05% w / w, about 0.1% w / w, or about 0.5% w / w to about 1% w / w, about 2% w / w, about 3% w / w, about 4% w / w, about 5% w / w, about 6% w / w, about 7% w / w, about 8% w / w, about 9% w / w, or about 10% w / w.
[0132] Nicotine components
[0133] In some embodiments, the pouched products of this disclosure may include nicotine compounds. Various nicotine compounds and methods of administration thereof are illustrated in Borschke’s U.S. Patent Application Publication No. 2011 / 0274628, which is incorporated herein by reference. As used herein, “nicotine compound” or “nicotine source” generally refers to a naturally occurring or synthetic nicotine compound that is not bound to plant material, meaning that the compound is at least partially purified and not contained within a plant structure (such as tobacco leaves). In some embodiments, the nicotine is naturally occurring and obtained as an extract from a species of the genus *Nicotiana* (e.g., tobacco). The nicotine may have enantiomers S(-)-nicotine, R(+)-nicotine, or a mixture of S(-)-nicotine and R(+)-nicotine. In some embodiments, the nicotine is in the form of S(-)-nicotine (e.g., in a form that is virtually entirely S(-)-nicotine) or mainly comprises S(-)-nicotine or a racemic mixture dominated by S(-)-nicotine (e.g., a mixture consisting of about 95 parts by weight of S(-)-nicotine and about 5 parts by weight of R(+)-nicotine). The nicotine can be used in an almost pure or substantially pure form. The nicotine used can have a purity of greater than about 95%, greater than about 98%, or greater than about 99% by weight.
[0134] In some embodiments, the composition may contain a nicotine component in the form of a free base, a salt, a complex, or a solvate. “Nicoleine component” refers to any suitable form of nicotine (e.g., a free base or a salt) suitable for at least partial oral absorption of the nicotine present. Typically, the nicotine component is selected from the group consisting of free nicotine bases and nicotine salts. In some embodiments, nicotine is in its free base form, which can be readily adsorbed onto, for example, a microcrystalline cellulose material to form a microcrystalline cellulose-nicotine carrier complex. See, for example, the discussion of free base form nicotine in U.S. Patent Application Publication No. 2004 / 0191322 by Hansson, which is incorporated herein by reference.
[0135] In some embodiments, at least a portion of the nicotine may be used in the form of a salt. Nicotine salts may be provided using the types of components and techniques shown in U.S. Patent No. 2,033,909 to Cox et al. and Perfetti, Beitrage Tabakforsch. Int., 12:43-54 (1983), which are incorporated herein by reference. Furthermore, nicotine salts may be obtained from sources such as Pfaltz and Bauer, Inc. and K&K Laboratories, Division of ICN Biochemicals, Inc. Typically, the nicotine component is selected from the group consisting of nicotine free bases and nicotine salts, such as nicotine hydrochloride, nicotine dihydrochloride, nicotine monotartrate, nicotine bitartrate, nicotine sulfate, nicotine salicylate, and zinc nicotine chloride. In some embodiments, the nicotine component or a portion thereof is a nicotine salt formed with one or more organic acids, as explained more fully below.
[0136] In some embodiments, at least a portion of the nicotine may be present in the form of a nicotine resin complex, wherein the nicotine is bound to an ion exchange resin, such as nicotine polacrilex, wherein the nicotine is bound to the ion exchange resin, such as a polymethacrylic acid resin (e.g., Amberlite). TM IRP64, Purolite TM C115HMR or Doshion® P551). See, for example, U.S. Patent No. 3,901,248 to Lichtneckert et al., which is incorporated herein by reference. Another example is a nicotine-polyacrylic acid carbomer complex, such as a complex formed with Carbopol® 974P. In some embodiments, nicotine may be present in the form of a nicotine-polyacrylic acid complex.
[0137] In some embodiments, it is desirable to provide an alkaline amine-containing oral product intended for oral use that maintains an initial alkaline amine content (e.g., nicotine content) during storage and delivers substantially all of the alkaline amine (e.g., nicotine) initially present in the oral product. In some such embodiments, nicotine or other alkaline amines are used in combination with at least a portion of an organic acid or its alkali metal salt (referred to herein as "ion pairing").
[0138] As disclosed herein, at least a portion of the basic amine (e.g., nicotine) is associated with at least a portion of an organic acid or its alkali metal salt. Depending on several variables (concentration, pH, nature of the organic acid, etc.), the basic amine present in the composition can exist in various forms, including ion-paired forms, in solution (i.e., completely solvated), as a free base, as a cation, as a salt, or any combination thereof. The relative amounts of the various components within the oral product composition can vary and are generally selected to provide the oral product with desired sensory and performance characteristics. In some embodiments, the association between the basic amine and at least a portion of the organic acid or its alkali metal salt is in the form of an ion pair between the basic amine and the conjugate base of the organic acid.
[0139] Ion pairing refers to the partial association of oppositely charged ions in a relatively concentrated solution to form independent chemical substances called ion pairs. The strength of association (i.e., ion pairing) depends on the electrostatic attraction between a positive ion and a negative ion (i.e., a protonated basic amine such as nicotine, with its conjugate base of an organic acid). A "conjugate base" is a base formed by the deprotonation of the corresponding acid (e.g., benzoate is the conjugate base of benzoic acid). On average, although ion pairs are constantly formed and dissociated, a certain amount of such ion pairs is present at any given time. In oral products as disclosed herein, and / or when the oral products are used orally (e.g., upon contact with saliva), basic amines (e.g., nicotine) are present at least partially as conjugate bases of organic acids in the form of ion pairs. It is not intended to be theoretically limited, but it is believed that such ion pairing can minimize the chemical degradation of basic amines and / or enhance the oral bioavailability of basic amines (e.g., nicotine). At alkaline pH values (e.g., from about 7.5 to about 9), some basic amines (e.g., nicotine) exist primarily as free bases, which have relatively low water solubility and low stability in terms of evaporation and oxidative decomposition, but high mucosal bioavailability. Conversely, at acidic pH values (e.g., from about 6.5 to about 4), some basic amines (e.g., nicotine) exist primarily as protonated forms, which have relatively high water solubility and higher stability in terms of evaporation and oxidative decomposition, but lower mucosal bioavailability.
[0140] It has been found that the stability, solubility, and bioavailability of nicotine in compositions intended for oral use can be improved by ion pairing or salt formation of nicotine with suitable organic acids and / or their conjugate bases. Specifically, nicotine-organic acid ion pairs with moderate lipophilicity produce favorable stability and absorption properties. Lipophilicity is conveniently measured by logP, which is the partition coefficient of a molecule between the lipophilic phase and the aqueous phase (typically octanol and water, respectively). Octanol-water partitioning favors the partitioning of basic amine-organic acid ion pairs into octanol, indicating that the basic amine present in the composition can be well absorbed through the oral mucosa.
[0141] As described above, at alkaline pH values (e.g., such as about 7.5 to about 9), nicotine exists primarily in its free base form (and therefore, its partition into octanol is high), while at acidic pH values (e.g., about 6.5 to about 4), nicotine exists primarily in its protonated form (and therefore, its partition into octanol is low). Ion pairs with certain organic acids (e.g., having logP values of about 1.4 to about 8.0, such as about 1.4 to about 4.5) allow nicotine to partition into octanol, which is consistent with the expected partitioning of nicotine into octanol at pH 8.4.
[0142] Those skilled in the art will recognize that the degree of ion pairing in the disclosed compositions, whether before or during consumer use, can vary depending on factors such as pH, the nature of the organic acid, the concentration of nicotine, the concentration of the organic acid or its conjugate base present in the composition, the water content of the composition, and the ionic strength of the composition. Those skilled in the art will also recognize that ion pairing is an equilibrium process influenced by the aforementioned variables. Therefore, quantifying the degree of ion pairing is difficult or impossible by calculation or direct observation. However, as disclosed herein, the presence of ion pairing can be demonstrated by alternative measurement indicators, such as the partitioning of nicotine between octanol and water, or the membrane permeability of aqueous solutions of basic amines with organic acids and / or their conjugate bases.
[0143] Typically, when present, the concentration of the nicotine component (calculated as free base) is at least about 0.001 wt% of the composition, such as in the range of about 0.001 wt% to about 10 wt%. In some embodiments, the nicotine component is present at a concentration of about 0.1% w / w to about 10 wt% based on free base and the total weight of the composition, such as, for example, about 0.1% w / w, about 0.2 wt%, about 0.3 wt%, about 0.4 wt%, about 0.5 wt%, about 0.6 wt%, about 0.7 wt%, about 0.8 wt%, or about 0.9 wt% to about 1 wt%, about 2 wt%, about 3 wt%, about 4 wt%, about 5 wt%, about 6 wt%, about 7 wt%, about 8 wt%, about 9 wt%, or about 10 wt%. In some embodiments, the nicotine component is present at a concentration of about 0.1% w / w to about 3% wt% based on free base and the total weight of the composition, such as, for example, about 0.1% w / w to about 2.5% wt%, about 0.1% wt% to about 2.0% wt%, about 0.1% wt% to about 1.5% wt%, or about 0.1% wt% to about 1% wt%. These ranges may also be applied to other active ingredients mentioned herein.
[0144] In some embodiments, the products or compositions disclosed herein may be characterized by being free of any nicotine component (e.g., any embodiment disclosed herein may be completely or substantially free of any nicotine component). “Substantially free” means that no nicotine has been intentionally added except for trace amounts that may be naturally present in, for example, plant materials. For example, some embodiments may be characterized by containing less than 0.001% by weight of nicotine, or less than 0.0001% by weight of nicotine, or even 0% by weight of nicotine, calculated as free base.
[0145] organic acids
[0146] As used herein, the term "organic acid" refers to an organic (i.e., carbon-based) compound characterized by acidity. Generally, organic acids are relatively weak acids (i.e., they do not completely dissociate in the presence of water), such as carboxylic acids (-CO2H) or sulfonic acids (-SO2OH). As used herein, reference to organic acid means intentionally added organic acid. In this respect, organic acids may be intentionally added as a specific compositional ingredient, rather than inherently present simply as a component of another compositional ingredient (e.g., small amounts of organic acids may be inherently present in compositional ingredients such as tobacco materials).
[0147] Suitable organic acids will typically have a range of lipophilicity (i.e., polarity that provides a suitable balance between water and organic solubility). Generally, as indicated by logP, the lipophilicity of a suitable organic acid will vary between about 1.4 and about 4.5 (more soluble in octanol than in water). In some embodiments, the organic acid has a logP value of about 1.5 to about 4.0, for example, about 1.5, about 2.0, about 2.5, or about 3.0 to about 3.5, about 4.0, about 4.5, or about 5.0. Particularly suitable organic acids have a logP value of about 1.7 to about 4, such as about 2.0, about 2.5, or about 3.0 to about 3.5 or about 4.0. In some embodiments, the organic acid has a logP value of about 2.5 to about 3.5. In some embodiments, organic acids outside this range may also be used in various amounts for various purposes, as further described below. For example, in some embodiments, the organic acid may have a logP value greater than about 4.5, such as about 4.5 to about 8.0. Specifically, the presence of certain solvents or solubilizers (e.g., glycerol or propylene glycol in the composition) can broaden the range of lipophilicity (i.e., logP values higher than 4.5, such as about 4.5 to about 8.0).
[0148] Not wanting to be confined to theory, it is believed that moderately lipophilic organic acids (e.g., logP of about 1.4 to about 4.5) form polar ion pairs with nicotine, thereby providing good octanol-water partitioning of said ion pairs, thus causing nicotine to partition into octanol rather than water. As discussed above, this partitioning into octanol indicates favorable oral bioavailability. In some embodiments, the organic acid has a logP value of about 1.4 to about 4.5, such as about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, or about 4.5. In some embodiments, the organic acid has a logP value of about 2.5 to about 3.5.
[0149] In some embodiments, the organic acid is a carboxylic acid or a sulfonic acid. The functional group of the carboxylic acid or sulfonic acid may be linked to any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group, having, for example, one to twenty carbon atoms (C1-C2). 20 In some embodiments, the organic acid is an alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl carboxylic acid or a sulfonic acid.
[0150] As used herein, "alkyl" refers to any straight-chain or branched hydrocarbon group. Alkyl groups can be saturated (i.e., entirely composed of...). sp 3 The carbon atom in the alkyl group can be present, or it can be unsaturated (i.e., having at least one unsaturated site). As used herein, the term "unsaturated" refers to the presence of carbon-carbon atoms at one or more positions within the alkyl group. sp 2Double bonds. Unsaturated alkyl groups can be monounsaturated or polyunsaturated. Representative straight-chain alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, and n-hexyl. Branched alkyl groups include, but are not limited to, isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and 2-methylbutyl. Representative unsaturated alkyl groups include, but are not limited to, ethylene (or vinyl), allyl, 1-butenyl, 2-butenyl, isobutenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, etc. Alkyl groups can be unsubstituted or substituted.
[0151] As used herein, "cycloalkyl" refers to a carbocyclic group, which can be monocyclic or bicyclic. Cycloalkyl groups include monocyclic rings having 3 to 7 carbon atoms, or bicyclic rings having 7 to 12 carbon atoms. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Cycloalkyl groups can be substituted or unsubstituted and may contain one or more unsaturated sites (e.g., cyclopentenyl or cyclohexenyl).
[0152] As used herein, the term "aryl" refers to a carbocyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl and naphthyl groups. Aryl groups can be substituted or unsubstituted.
[0153] As used herein, “heteroaryl” and “heterocyclic alkyl” refer to aromatic or non-aromatic ring systems, respectively, in which one or more ring atoms are heteroatoms, such as nitrogen, oxygen, and sulfur. A heteroaryl or heterocyclic alkyl group comprises up to 20 carbon atoms and 1 to 3 heteroatoms selected from N, O, and S. A heteroaryl or heterocyclic alkyl group can be a monocyclic group having 3 to 7 ring members (e.g., 2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, and S), or a bicyclic group having 7 to 10 ring members (e.g., 4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, and S), such as bicyclic [4,5], [5,5], [5,6], or [6,6] systems. Examples of heteroaryl groups, as exemplary and not limiting, include: pyridyl, thiazolyl, tetrahydrothiophene, pyrimidinyl, furanyl, thiophene, pyrroleyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthyl, indoleyl, indoleenyl, quinolinyl, isoquinolinyl, benzimidazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indoleazinyl, isoindoleyl, 3H-indoleyl, 1H-indazolyl, purineyl, 4 H-quinazinyl, phthalazinyl, naphridinyl, quinoxalinyl, quinazolinyl, cinnaphthyl, pteridinyl, 4aH-carbazoyl, carbazoyl, phenanthridine, acridineyl, pyrimidinyl, phenanthrololinyl, phenazinyl, phenothiazinyl, furazinyl, phenotoxazinyl, isochromyl, chromanyl, imidazoalkyl, imidazolinyl, pyrazolyl, pyrazolyl, benzotriazolyl, benzisoxazolyl, and isatinoyl. Examples of heterocyclic alkyl groups, as exemplary and not limiting, include: dihydropyridinyl, tetrahydropyridinyl (piperidinyl), tetrahydrothiophenyl, piperidinyl, 4-piperidinoneyl, pyrrolyl, 2-pyrrolyl, tetrahydrofuranyl, tetrahydropyranyl, bis(tetrahydropyran)yl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, piperazinyl, quininecycloyl, and morpholinyl. Heteroaryl and heterocyclic alkyl groups can be substituted or unsubstituted.
[0154] As used herein and applicable to any of the alkyl, aryl, cycloalkyl, heteroaryl, or heterocyclic groups described above, "substituted" means that one or more hydrogen atoms are independently substituted by a substituent. Typical substituents include, but are not limited to, -Cl, -Br, -F, alkyl, -OH, -OCH3, NH2, -NHCH3, -N(CH3)2, -CN, -NC(=O)CH3, -C(=O)-, -C(=O)NH2, and -C(=O)N(CH3)2. Whenever a group is described as "optionally substituted," the group may be substituted by one or more of the above substituents, each chosen independently. In some embodiments, the substituent may be one or more methyl groups or one or more hydroxyl groups.
[0155] In some embodiments, the organic acid is an alkyl carboxylic acid. Non-limiting examples of alkyl carboxylic acids include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, etc.
[0156] In some embodiments, the organic acid is an alkyl sulfonic acid. Non-limiting examples of alkyl sulfonic acids include propanesulfonic acid, heptanesulfonic acid, and octanesulfonic acid.
[0157] In some embodiments, the alkyl carboxylic acid or sulfonic acid is substituted with one or more hydroxyl groups. Non-limiting examples include glycolic acid, 4-hydroxybutyric acid, and lactic acid.
[0158] In some embodiments, the organic acid may include more than one carboxylic acid group or more than one sulfonic acid group (e.g., two, three, or more carboxylic acid groups). Non-limiting examples include oxalic acid, fumaric acid, maleic acid, and glutaric acid. In organic acids containing multiple carboxylic acid groups (e.g., two to four carboxylic acid groups), one or more of said carboxylic acid groups may be esterified. Non-limiting examples include monoethyl succinate, monomethyl fumarate, monomethyl citrate, or dimethyl succinate.
[0159] In some embodiments, the organic acid may include more than one carboxylic acid group and one or more hydroxyl groups. Non-limiting examples of such acids include tartaric acid, citric acid, etc.
[0160] In some embodiments, the organic acid is an aryl carboxylic acid or an aryl sulfonic acid. Non-limiting examples of aryl carboxylic acids and sulfonic acids include benzoic acid, methylbenzoic acid, salicylic acid, benzenesulfonic acid, and p-toluenesulfonic acid.
[0161] Other non-limiting examples of organic acids that can be used in some embodiments include 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetaminobenzoic acid, 4-aminosalicylic acid, adipic acid, ascorbic acid (L), and aspartic acid (L). α-Methylbutyric acid, camphoric acid (+), camphor-10-sulfonic acid (+), cinnamic acid, cyclohexanoic acid, dodecyl sulfate, ethane-1,2-disulfonic acid, ethanesulfonic acid, furanoic acid, galactosic acid, gentian acid, glucoheponic acid, gluconic acid, glucuronic acid, glutamic acid, glycerophosphate, glycolic acid, hippuric acid, isobutyric acid, isovaleric acid, lactobionic acid, lauric acid, acetylpropionic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, oleic acid, palmitic acid, pamoic acid, phenylacetic acid, pyroglutamic acid, pyruvic acid, sebacic acid, stearic acid, and undecenoic acid.
[0162] Examples of suitable acids include, but are not limited to, the list of organic acids in Table 1.
[0163] Table 1. Non-limiting examples of suitable organic acids Values obtained from PubChem or calculated.
[0164] In addition to considering logP value, the selection of organic acids can also depend on additional properties. For example, organic acids should be generally recognized as safe for human consumption and possess acceptable flavor, odor, volatility, and stability. Determining suitable organic acids is within the capabilities of those skilled in the art.
[0165] In some embodiments, the organic acid is a monoester of a dicarboxylic acid or a polycarboxylic acid. In some embodiments, the dicarboxylic acid is malonic acid, succinic acid, glutaric acid, adipic acid, fumaric acid, maleic acid, or a combination thereof. In some embodiments, the dicarboxylic acid is succinic acid, glutaric acid, fumaric acid, maleic acid, or a combination thereof. In some embodiments, the dicarboxylic acid is succinic acid, glutaric acid, or a combination thereof.
[0166] In some embodiments, the alcohol forming the monoester of the dicarboxylic acid is a lipophilic alcohol. Examples of suitable lipophilic alcohols include, but are not limited to, octanol, menthol, and tocopherol. In some embodiments, the organic acid is an octyl monoester of the dicarboxylic acid, such as octyl succinate, octyl fumarate, etc. In some embodiments, the organic acid is a monomenthyl ester of the dicarboxylic acid. Because certain menthyl esters can provide a cooling sensation when used in products containing the compositions described herein, they are suitable for use in the oral compositions described herein. In some embodiments, the organic acid is monomenthyl succinate, monomenthyl fumarate, monomenthyl glutarate, or combinations thereof. In some embodiments, the organic acid is a monotocopherol ester of the dicarboxylic acid. Because certain tocopherol esters can provide antioxidant effects, they are suitable for use in the oral compositions described herein. In some embodiments, the organic acid is tocopherol succinate, tocopherol fumarate, tocopherol glutarate, or combinations thereof.
[0167] In some embodiments, the organic acid is a carotenoid derivative having one or more carboxylic acid (groups). Carotenoids are tetraterpenes, meaning they consist of eight isoprene molecules and contain 40 carbon atoms. Therefore, they are generally lipophilic due to the presence of long unsaturated aliphatic chains and are typically yellow, orange, or red. Certain carotenoid derivatives can be advantageous in oral compositions because they both promote ion pairing and act as colorants in the composition. In some embodiments, the organic acid is (2E,4E,6E,8E,10E,12E,14E,16Z,18E)-20-methoxy-4,8,13,17-tetramethyl-20-oxoeicosano-2,4,6,8,10,12,14,16,18-nonenoic acid (annatto) or its isomers. annatto is produced from the annatto tree (*Annona squamosa*). Bixa orellana A carotenoid, a naturally occurring pigment found in the seeds of the annatto tree, provides its red-orange color. Natto is soluble in fats and alcohols but insoluble in water. When isolated, it is chemically unstable and undergoes isomerization to become the double-bonded isomer trans-annatto (β-annatto), with the following structure:
[0168] In some embodiments, the organic acid is (2E,4E,6E,8E,10E,12E,14E,16E,18E)-4,8,13,17-tetramethyleicosicocarbon-2,4,6,8,10,12,14,16,18-nonanediol (norannatin), which is a water-soluble hydrolysis product of annatin and has the following structure:
[0169] In some embodiments, more than one organic acid may be present. For example, the composition may include two, three, four, or more organic acids. Therefore, when "one organic acid" is mentioned herein, it also includes a mixture of two or more organic acids. The relative amounts of the various organic acids can vary. For example, the composition may contain equal amounts of two, three, or more organic acids, or it may contain different relative amounts. In this way, certain organic acids with logP values outside the desired range (e.g., citric acid or myristic acid) can be combined with other organic acids so that the average logP of the combination falls within the desired range. In some embodiments, it may be desirable to include organic acids with logP values outside the desired range in the composition for purposes such as, but not limited to, providing desired sensory properties, stability, or as a flavor component. Furthermore, certain lipophilic organic acids have undesirable flavor and / or aroma characteristics, which would make them unsuitable as the sole organic acid in a composition (e.g., present in equimolar or greater amounts relative to nicotine). Without being bound by theory, it is believed that combinations of different organic acids can provide the desired ion pairings, while the concentration of any single organic acid in the composition remains below a threshold that is considered sensorily unacceptable.
[0170] In some embodiments, the composition comprises an organic acid, which is a monoester of a dicarboxylic acid or a carotenoid derivative having one or more carboxylic acid groups as described above, and further comprises additional organic acids or salts thereof. In some embodiments, the additional organic acid is benzoic acid, its alkali metal salt, or a combination thereof.
[0171] In some embodiments, the composition comprises an alkali metal salt of an organic acid. For example, at least a portion of the organic acid may be present in the composition as an alkali metal salt. Suitable alkali metal salts include lithium, sodium, and potassium salts. In some embodiments, the alkali metal is sodium or potassium. In some embodiments, the alkali metal is sodium. In some embodiments, the composition comprises an organic acid and a sodium salt of the organic acid.
[0172] In some embodiments, the weight ratio of the organic acid to its sodium salt (or other alkali metal salt) is from about 0.1 to about 10, such as about 0.1, about 0.25, about 0.3, about 0.5, about 0.75, or about 1 to about 2, about 5, or about 10. For example, in some embodiments, both the organic acid and its sodium salt are added to the other components of the composition, wherein the added organic acid is in greater quantity than, equimolar with, or a fraction of the amount of sodium salt. Those skilled in the art will recognize that the relative amounts will be determined by the desired pH and ionic strength of the composition. For example, an amount of organic acid may be added to provide the desired pH level of the composition, while an amount of alkali metal (e.g., sodium) salt may be added to provide the desired degree of ion pairing. As those skilled in the art will understand, the amount of organic acid (i.e., in its protonated form) present in the composition relative to the amount of alkali metal salt or conjugate base present in the composition will vary depending on the pH of the composition and the pKa of the organic acid, as well as the actual relative amount initially added to the composition.
[0173] The amount of organic acid or its alkali metal salt present in the composition relative to a basic amine (e.g., nicotine) can vary. Generally, as the concentration of the organic acid (or its conjugate base) increases, the percentage of the basic amine (e.g., nicotine) ion-paired with the organic acid increases. This typically increases the extent to which the basic amine (e.g., nicotine) in ion-pair form is partitioned in octanol relative to water, as measured in logP (log10 of the partition coefficient). In some embodiments, the composition comprises about 0.05, about 0.1, about 1, about 1.5, about 2, or about 5 to about 10, about 15, or about 20 molar equivalents of the organic acid, its alkali metal salt, or combinations thereof, calculated as the free base of the basic amine (e.g., nicotine).
[0174] In some embodiments, the composition comprises, on a free base basis, about 2 to about 10, or about 2 to about 5 molar equivalents of the organic acid, its alkali metal salt, or combinations thereof relative to a basic amine (e.g., nicotine). In some embodiments, the organic acid, its alkali metal salt, or combinations thereof is present in a molar ratio of about 2, about 3, about 4, or about 5 to about 6, about 7, about 8, about 9, or about 10 to the basic amine (e.g., nicotine). In embodiments where more than one organic acid, its alkali metal salt, or both are present, it should be understood that such molar ratios reflect the total number of organic acids present.
[0175] In some embodiments, the amount of organic acid included is sufficient to provide a composition pH of about 4.0 to about 9.0, such as about 4.5 to about 7.0, or about 5.5 to about 7.0, about 4.0 to about 5.5, or about 7.0 to about 9.0. In some embodiments, the amount of organic acid included is sufficient to provide a composition pH of about 4.5 to about 6.5, for example, about 4.5, about 5.0, or about 5.5 to about 6.0 or about 6.5. In some embodiments, the organic acid is provided in an amount sufficient to provide a composition pH of about 5.5 to about 6.5, for example, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, or about 6.0 to about 6.1, about 6.2, about 6.3, about 6.4, or about 6.5. In some embodiments, an inorganic acid (e.g., hydrochloric acid, sulfuric acid, phosphoric acid, etc.) is added to adjust the pH of the composition to the desired value.
[0176] In some embodiments, the organic acid, as a free acid, is added to other composition components in pure substance form (i.e., in its solid or liquid state) or in a solution, such as in water. In some embodiments, an alkali metal salt of the organic acid is added to other composition components in pure substance form or in a solution, such as in water. In some embodiments, the organic acid and a basic amine (e.g., nicotine) are combined to form a salt before being added to the composition, or the salt is formed within the composition and exists therein as a salt. In some embodiments, the organic acid and the basic amine (e.g., nicotine) exist as separate components in the composition and form ion pairs upon contact with moisture (e.g., saliva from a user's mouth).
[0177] In some embodiments, the organic acid, as a free acid, is added to other composition components in pure substance form (i.e., in its solid or liquid state) or in a solution, such as in water. In some embodiments, an alkali metal salt of the organic acid is added to other composition components in pure substance form or in a solution, such as in water. In some embodiments, the organic acid and a basic amine (e.g., nicotine) are combined to form a salt before being added to the composition, or the salt is formed within the composition and exists therein as a salt. In some embodiments, the organic acid and the basic amine (e.g., nicotine) exist as separate components in the composition and form ion pairs upon contact with moisture (e.g., saliva from a user's mouth).
[0178] In some embodiments, the oral composition comprises nicotine benzoate and sodium benzoate, wherein at least a portion of the nicotine and benzoate ions are in an ion-paired form. In some embodiments, the composition comprises nicotine benzoate, sodium benzoate, and an organic acid, an alkali metal salt of an organic acid, or a combination thereof, wherein the organic acid has a logP value of about 1 to about 12, and wherein the organic acid is a monoester of a dicarboxylic acid or a carotenoid derivative having one or more carboxylic acid (groups).
[0179] In some embodiments, the oral composition further comprises a solubilizer to increase the solubility of one or more organic acids or their salts. Suitable solubilizers include, but are not limited to, humectants as described herein, such as glycerin or propylene glycol.
[0180] Terpenes
[0181] The active ingredients applicable to this disclosure can also be classified as terpenes, many of which are associated with biological effects, such as sedative effects. Terpenes are considered to possess (C5H8) n The general formula includes monoterpenes, sesquiterpenes, and diterpenes. Terpenes can be acyclic, monocyclic, or bicyclic in structure. Examples include β-caryophyllene, linalool, limonene, β-citronellol, linalyl acetate, pinene (α or β), geraniol, carvone, eucalyptol, menthone, isomenthone, piperonone, myrcene, β-bourbonene, and germacrene, which can be used alone or in combination.
[0182] In this regard, suitable terpenes include so-called "C10" terpenes (i.e., those comprising 10 carbon atoms) and so-called "C15" terpenes (i.e., those comprising 15 carbon atoms). In some embodiments, the active ingredient comprises more than one terpene. For example, the active ingredient may comprise one, two, three, four, five, six, seven, eight, nine, ten, or more terpenes as defined herein. In some embodiments, the terpenes are selected from pinene (α and β), geraniol, linalool, limonene, carvone, eucalyptol, menthone, isomenthone, piperonone, myrcene, β-boronene, gemmaene, and mixtures thereof.
[0183] Drug ingredients
[0184] In some embodiments, the active ingredient includes an active pharmaceutical ingredient (API). The API can be any known agent suitable for therapeutic, preventative, or diagnostic purposes. These can include, for example, synthetic organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, phospholipids, inorganic compounds (e.g., magnesium, selenium, zinc, nitrates), neurotransmitters or their precursors (e.g., serotonin, 5-hydroxytryptophan, oxysalicylate, acetylcholine, dopamine, melatonin), and nucleic acid sequences having therapeutic, preventative, or diagnostic activity. Non-limiting examples of APIs include analgesics and antipyretics (e.g., acetylsalicylic acid, acetaminophen, 3-(4-isobutylphenyl)propionic acid), phosphatidylserine, inositol, docosahexaenoic acid (DHA, Omega-3), arachidonic acid (AA, Omega-6), S-adenosylmethionine (SAM), β-hydroxy-β-methylbutyric acid (HMB), citicoline (cytidine-5'-bisphosphate choline), and cotinine. In some embodiments, the active ingredient includes citicoline. In some embodiments, the active ingredient is a combination of citicoline, caffeine, theanine, and ginseng. In some embodiments, the active ingredient includes sunflower lecithin. In some embodiments, the active ingredient is a combination of sunflower lecithin, caffeine, theanine, and ginseng.
[0185] The amount of API can vary. For example, when present, the API is typically concentrated from about 0.001% w / w to about 10% wt based on the total weight of the composition, such as about 0.01% w / w, about 0.02% w / w, about 0.03% w / w, about 0.04% w / w, about 0.05% w / w, about 0.06% w / w, about 0.07% w / w, about 0.08% w / w, about 0.09% w / w, about 0.1% w / w, about 0.2% w / w, about 0.3% w / w, about 0.4% w / w, about 0.5% w / w, about 0.6% w / w, about 0.7% w / w, about 0.8% w / w, or about 0.9% w / w, or about 1% w / w to about 2% w / w, about 3% w / w, about 4% w / w, about 5% w / w, about 6% w / w, about 7% w / w, about 8% w / w, about 9% w / w, or about 10% w / w.
[0186] In some embodiments, the composition is substantially free of any APIs. “Substantially free of any APIs” means that the composition does not contain and explicitly excludes the presence of any APIs as defined herein (such as any FDA-approved therapeutic agent intended to treat any disease or condition).
[0187] Tobacco materials
[0188] In some embodiments, the composition may include tobacco material. The tobacco material may vary in species, type, and form. Generally, the tobacco material is derived from harvested tobacco varieties (…). NicotianaThe species are obtained from plants. Examples of plants in the genus *Nicotiana* include: *N. tabacum*, *N. rustica*, *N. alata*, *N. arentsii*, *N. excelsior*, *N. forgetiana*, *N. glauca*, *N. glutinosa*, *N. gossei*, *N. kawakamii*, *N. knightiana*, *N. langsdorffi*, *N. otophora*, *N. setchelli*, *N. sylvestris*, *N. tomentosa*, *N. tomentosiformis*, *N. undulata*, *N. xsanderae*, *N. africana*, and *N. clasping stem*. The following are listed: *N. amplexicaulis*, *N. benavidesii*, *N. bonariensis*, *N. debneyi*, *N. longiflora*, *N. maritina*, *N. megalosiphon*, *N. occidentalis*, *N. paniculata*, *N. plumbaginifolia*, *N. raimondii*, *N. rosulata*, *N. simulans*, *N. stocktonii*, *N. suaveolens*, *N. umbratica*, *N. velutina*, *N. wigandioides*, *N. acaulis*, *N. acuminata*, *N. narrow-leaved*. (N. attenuata), N. benthamiana, N. cavicola, N. clevelandii, N. cordifolia, N. corymbosa, N. fragrans, N. goodspeedii, N. linearis, N. moses.The species include *N. miersii*, *N. nudicaulis*, *N. obtusifolia*, *N. occidentalis subsp. Hersperis*, *N. pauciflora*, *N. petunioides*, *N. quadrivalvis*, *N. repanda*, *N. rotundifolia*, *N. solanifolia*, and *N. spegazzinii*. Other representative plants from the genus Nicotiana are shown in Goodspeed, *The Genus Nicotiana* (Chonica Botanica) (1954); U.S. Patent No. 4,660,577 to Sensabaugh, Jr. et al.; U.S. Patent No. 5,387,416 to White et al.; U.S. Patent No. 7,025,066 to Lawson et al.; U.S. Patent No. 7,798,153 to Lawrence, Jr.; and U.S. Patent No. 8,186,360 to Marshall et al.; all of which are incorporated herein by reference. Various types of tobacco, cultivation techniques, and harvesting techniques are described in *Tobacco Production, Chemistry and Technology* (1999) by Davis et al. (eds.), which is incorporated herein by reference.
[0189] Suitable tobacco materials can be obtained from tobacco plants derived using genetic modification or hybridization breeding techniques (e.g., tobacco plants can be genetically engineered or hybridized to increase or decrease the yield of components, traits, or attributes). See, for example, the types of plant genetic modifications shown in the following publications: U.S. Patent No. 5,539,093 to Fitzmaurice et al.; U.S. Patent No. 5,668,295 to Wahab et al.; U.S. Patent No. 5,705,624 to Fitzmaurice et al.; U.S. Patent No. 5,844,119 to Weigl; U.S. Patent No. 6,730,832 to Dominguez et al.; U.S. Patent No. 7,173,170 to Liu et al.; U.S. Patent No. 7,208,659 to Colliver et al.; and U.S. Patent No. 7,230,160 to Benning et al.; U.S. Patent Application Publication No. 2006 / 0236434 to Conkling et al.; and PCT WO2008 / 103935 to Nielsen et al. See also the tobacco types listed in U.S. Patent No. 4,660,577 to Sensabaugh, Jr. et al.; U.S. Patent No. 5,387,416 to White et al.; and U.S. Patent No. 6,730,832 to Dominguez et al., all of which are incorporated herein by reference.
[0190] In some embodiments, tobacco plants can be selected based on the abundance of various compounds present therein. For example, plants that produce higher amounts of one or more target isolated compounds can be selected. In some embodiments, tobacco plants (e.g., *Galpao communa*) are specifically cultivated for their rich leaf surface compounds. Tobacco plants can be grown in greenhouses, growing rooms, or in outdoor fields, or hydroponically.
[0191] Parts or portions of tobacco plants may be included in the mixtures disclosed herein. For example, virtually all parts of the plant (e.g., the whole plant) may be harvested and used directly. Alternatively, parts or segments of the plant may be harvested or separated after harvest for further use. For example, flowers, leaves, stems, culms, roots, seeds, and various combinations thereof may be separated for further use or processing. In some embodiments, the tobacco material includes tobacco leaves (leaflets). The mixtures disclosed herein may include processed tobacco parts or segments, flavored and aged tobacco that retains substantially the form of natural leaves and / or stems, tobacco extracts, extracted tobacco pulp (e.g., using water as a solvent), or mixtures of the above (e.g., a mixture combining extracted tobacco pulp with granular flavored and aged natural tobacco leaves).
[0192] In some embodiments, the tobacco material comprises solid tobacco material selected from the group consisting of leaves and stems. The tobacco used in the blend typically comprises tobacco leaves, or a blend of tobacco leaves and stems (at least partially smoked). A portion of the tobacco in the blend may be in a processed form, such as processed tobacco stems (e.g., cut and rolled tobacco stems, cut, rolled and expanded tobacco stems, or cut and expanded tobacco stems), or volume-expanded tobacco (e.g., expanded tobacco, such as dry ice expanded tobacco (DIET)). See, for example, the tobacco expansion processes shown in U.S. Patent No. 4,340,073 to de la Burde et al.; U.S. Patent No. 5,259,403 to Guy et al.; and U.S. Patent Nos. 5,908,032 and 7,556,047 to Poindexter et al., all of which are incorporated herein by reference. Additionally, the blend may optionally include fermented tobacco. See also Atchley et al.’s PCTWO 2005 / 063060 for types of tobacco processing techniques, which are incorporated herein by reference.
[0193] Tobacco material is typically used in the form of particles (i.e., fragments, ground particles, granules, or powder). The methods of providing finely ground or powdered tobacco material can vary. Plant parts or fragments are typically crushed, ground, or mechanically milled into particle form using equipment and techniques for grinding, milling, etc. During crushing or milling (using equipment such as hammer mills, cutter heads, air-controlled mills, etc.), the plant material is usually in a relatively dry state. For example, when the moisture content of a tobacco part or fragment is less than about 15% by weight or less than about 5% by weight, it can be ground or milled. Tobacco material is sometimes used in the form of parts or fragments with an average particle size between 1.4 mm and 250 micrometers. In some cases, the size of the tobacco particles can be set to pass through a sieve to obtain the desired particle size range. If necessary, air grading equipment can be used to ensure that small-sized tobacco particles of the desired size or size range can be collected. If necessary, granular tobacco fragments of different sizes can be mixed together.
[0194] To prepare oral products, harvested tobacco species are typically subjected to a conditioning process. The tobacco material incorporated into the mixture to be included in products as described herein is that which has been properly conditioned and / or aged. Various conditioning processes for different types of tobacco are described in *Tobacco Production, Chemistry and Technology* (1999) by Davis et al. (eds.), and examples of techniques and conditions for conditioning flue-cured tobacco are shown in Nestor et al., Beitrage Tabakforsch Int., 20, 467-475 (2003), and Peele's U.S. Patent No. 6,895,974, which are incorporated herein by reference. Representative techniques and conditions for air-curing tobacco include Groves et al.'s U.S. Patent No. 7,650,892; Roton et al., Beitrage Tabakforsch. Int. , 21, 305-320 (2005) and Staaf et al, Beitrage Tabakforsch. Int. As shown in , 21, 321-330 (2005), the literature is incorporated herein by reference. Certain types of tobacco can undergo alternative types of conditioning processes, such as smoked (smoked) or sun-dried (dried). In some embodiments, the tobacco materials that may be used include flue-cured or Virginia tobacco (e.g., K326), burley tobacco, sun-dried tobacco (e.g., Indian Kurnool and aromatic tobacco, including Katerini, Prelip, Komotini, Xanthi and Yambol tobacco), Maryland tobacco, dark tobacco, dark flame-modified tobacco, dark air-modified tobacco (e.g., Madole, Passanda, Cubano, Jatin and Bezuki tobacco), light air-modified tobacco (e.g., North Wisconsin and Galpao tobacco), Indian air-modified tobacco, Red Russian and Rustica tobacco, as well as various other rare or specialty tobaccos and various blends of any of the aforementioned tobaccos.
[0195] The tobacco material may also be in a so-called "blended" form. For example, the tobacco material may include a mixture of portions or fragments of flue-cured tobacco, burley tobacco (e.g., Malawi burley tobacco), and aromatic tobacco (e.g., as tobacco composed of or derived from tobacco leaves, or a mixture of tobacco leaves and tobacco stems). For example, a representative blend may contain about 30 to about 70 parts of burley tobacco (e.g., leaves, or leaves and stems) and about 30 to about 70 parts of flue-cured tobacco (e.g., stems, leaves, or leaves and stems) by dry weight. Other exemplary tobacco blends may contain about 75 parts of flue-cured tobacco, about 15 parts of burley tobacco, and about 10 parts of aromatic tobacco by dry weight; or about 65 parts of flue-cured tobacco, about 25 parts of burley tobacco, and about 10 parts of aromatic tobacco; or about 65 parts of flue-cured tobacco, about 10 parts of burley tobacco, and about 25 parts of aromatic tobacco by dry weight. Other exemplary tobacco blends may contain about 20 to about 30 parts of aromatic tobacco and about 70 to about 80 parts of flue-cured tobacco by dry weight.
[0196] The tobacco materials used in this disclosure can be subjected to processes such as fermentation and bleaching. If desired, the tobacco materials can be subjected to controlled heat treatment, such as irradiation, pasteurization, or otherwise. Such treatment processes are detailed in, for example, U.S. Patent No. 8,061,362 to Mua et al., which is incorporated herein by reference. In some embodiments, the tobacco materials can be treated with water and an additive capable of inhibiting the reaction of asparagine to form acrylamide when the tobacco materials are heated (e.g., additives selected from the group consisting of: lysine, glycine, histidine, alanine, methionine, cysteine, glutamic acid, aspartic acid, proline, phenylalanine, valine, arginine, compositions containing divalent and trivalent cations, asparaginases, certain non-reducing sugars, certain reducing agents, phenolic compounds, certain compounds having at least one free thiol group or functionality, oxidizing agents, oxidation catalysts, natural plant extracts (e.g., rosemary extract) and combinations thereof). See, for example, the types of processing described in U.S. Patent Publications 8,434,496, 8,944,072, and 8,991,403 by Chen et al., the entire contents of which are incorporated herein by reference. Other methods are disclosed, for example, in International Patent Application Publications WO2013 / 122948, WO / 2020 / 128971, WO / 2021 / 048769, WO / 2021 / 048768, WO / 2021 / 048770, and International Patent Application PCT / IB2021 / 058063, the entire contents of which are incorporated herein by reference. In some embodiments, this type of treatment is useful where the previously described process requires heating of the raw tobacco material.
[0197] In some embodiments, the type of tobacco material is selected such that it is initially visually lighter in color than other tobacco materials (e.g., bleached or whitened). In some embodiments, the tobacco pulp can be whitened according to any means known in the art. For example, bleached tobacco material produced by employing various bleaching agents or oxidants and oxidizing catalysts can be used. Exemplary oxidants include peroxides (e.g., hydrogen peroxide), chlorites, chlorates, perchlorates, hypochlorites, ozone, ammonia, potassium permanganate, and combinations thereof. Exemplary oxidizing catalysts are titanium dioxide, manganese dioxide, and combinations thereof. Processes for treating tobacco with bleaching agents are discussed, for example, Daniels, Jr.'s U.S. Patent No. 787,611; Oelenheinz's U.S. Patent No. 1,086,306; Delling's U.S. Patent No. 1,437,095; Rosenhoch's U.S. Patent No. 1,757,477; Hawkinson's U.S. Patent No. 2,122,421; Baier's U.S. Patent No. 2,148,147; Baier's U.S. Patent No. 2,170,107; Baier's U.S. Patent No. 2,274,649; Prats et al.'s U.S. Patent No. 2,770,239; Rosen's U.S. Patent No. 3,612,065; R Rosen's U.S. Patent No. 3,851,653; Rosen's U.S. Patent No. 3,889,689; Minami's U.S. Patent No. 3,943,940; Rosen's U.S. Patent No. 3,943,945; Rainer's U.S. Patent No. 4,143,666; Campbell's U.S. Patent No. 4,194,514; Rainer et al.'s U.S. Patent Nos. 4,366,823, 4,366,824, and 4,388,933; Schmekel et al.'s U.S. Patent No. 4,641,667; Berger's U.S. Patent No. 5,713,376; Byrd U.S. Patent No. 9,339,058 to Jr. et al.; U.S. Patent No. 9,420,825 to Beeson et al.; and U.S. Patent No. 9,950,858 to Byrd Jr. et al.; and U.S. Patent Application Publication No. 2012 / 0067361 to Bjorkholm et al.; U.S. Patent Application Publication No. 2016 / 0073686 to Crooks; U.S. Patent Application Publication No. 2017 / 0020183 to Bjorkholm; and U.S. Patent Application Publication No. 2017 / 0112183 to Bjorkholm; and PCT Publication No. WO1996 / 031255 to Giolvas; and PCT Publication No. WO2018 / 083114 to Bjorkholm. All these references are incorporated herein by reference.
[0198] In some embodiments, the whitening tobacco material may have an ISO brightness of at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80%. In some embodiments, the whitening tobacco material may have an ISO brightness in the range of about 50% to about 90%, about 55% to about 75%, or about 60% to about 70%. The ISO brightness can be measured according to ISO 3688:1999 or ISO 2470-1:2016.
[0199] In some embodiments, the bleached tobacco material can be characterized as being lighter in color (e.g., "bleached") compared to untreated tobacco material. White is typically defined with reference to the International Commission on Illumination (CIE) chromaticity diagram. In some embodiments, the bleached tobacco material can be characterized as being closer to pure white on the chromaticity diagram compared to untreated tobacco material.
[0200] In some embodiments, the tobacco material can be processed to extract soluble components of the tobacco material. As used herein, "tobacco extract" refers to a separated component of the tobacco material extracted from solid tobacco pulp by contacting a solvent with the tobacco material in an extraction process. Various extraction techniques for tobacco material can be used to provide both tobacco extracts and solid tobacco material. See, for example, the extraction method described in U.S. Patent Application Publication No. 2011 / 0247640, Beeson et al., which is incorporated herein by reference. Other exemplary techniques for extracting tobacco components are described in the following U.S. patents: Fiore No. 4,144,895; Osborne, Jr. et al. No. 4,150,677; Reid No. 4,267,847; Wildman et al. No. 4,289,147; Brummer et al. No. 4,351,346; Brummer et al. No. 4,359,059; Muller No. 4,506,682; Keritsis No. 4,589,428; Soga et al. No. 4,605,016; Poulose et al. No. 4,716,911; Niven, Jr. et al. No. 4,727,889; Bernasek et al. No. 4,887,618; Clapp et al. No. 4,941,484; Fagg et al. No. 4,967,771; Roberts et al. No. 4,986,286; Fagg et al. No. 5,005,593; Grubbs et al. No. 5,018,540; White et al. No. 5,060,669; Fagg No. 5,065,775; White et al. No. 5,074,319; White et al. No. 5,099,862; White et al. No. 5,121,757; Fagg No. 5,131,414; Munoz et al. No. 5,131,415; Fagg No. 5,148,819; Kramer No. 5 Nos. 197,494; Smith et al. No. 5,230,354; Fagg No. 5,234,008; Smith No. 5,243,999; Raymond et al. No. 5,301,694; Gonzalez-Parra et al. No. 5,318,050; Teague No. 5,343,879; Newton No. 5,360,022; Clapp et al. No. 5,435,325; Brinkley et al. No. 5,445,169; Lauterbach No. 6,131,584; Kierulff et al. No. 6,298,859; Mua et al. No. 6,772,767; and Thompson No. 7,337,782 are all incorporated herein by reference in their entirety.
[0201] Typical ranges of tobacco material content can vary depending on the nature and type of the tobacco material and the intended effect on the final composition, with exemplary ranges based on the total weight of the mixture being up to about 30% by weight (or up to about 20% by weight, or up to about 10% by weight, or up to about 5% by weight) (e.g., about 0.1% to about 15% by weight). In some embodiments, tobacco material (e.g., whitening tobacco material) is included in relatively small amounts (e.g., about 0.01% to about 0.1% by weight).
[0202] Other additives
[0203] Other additives may be included in the disclosed compositions. For example, the compositions may be processed, blended, formulated, combined, and / or mixed with other materials or ingredients. The additives may be artificial additives or may be obtained from or derived from herbal or biological sources. Examples of further types of additives include additional thickeners or gelling agents (e.g., fish gelatin), emulsifiers, preservatives (e.g., potassium sorbate, etc.), relatively water-soluble zinc or magnesium salts (e.g., magnesium gluconate or zinc gluconate) selected for compositions with high water solubility, or relatively water-insoluble zinc or magnesium salts (e.g., magnesium oxide or zinc oxide) selected for compositions with reduced water solubility, disintegrants, or combinations thereof. See, for example, U.S. Patent No. 9,237,769 to Mua et al., U.S. Patent No. 7,861,728 to Holton, Jr. et al., U.S. Patent Publication No. 2010 / 0291245 to Gao et al., and U.S. Patent Publication No. 2007 / 0062549 to Holton, Jr., and the manner and method of using those components, each of which is incorporated herein by reference. Typical ranges of the amount of such additives may vary depending on the nature and function of the additive and the intended effect on the final composition, with exemplary ranges being up to about 10% by weight (e.g., about 0.1% to about 5% by weight) based on the total weight of the composition.
[0204] The aforementioned additives may be used together (e.g., as an additive formulation) or separately (e.g., individual additive components may be added at different stages involved in the preparation of the final composition). Furthermore, in the final product, additives of the aforementioned types may be in encapsulated form. Examples of encapsulated additives are described, for example, in Atchley's WO2010 / 132444, which has previously been incorporated herein by reference.
[0205] In some implementations, cellulose sponge oral products can be encapsulated within a fleece material to form a pouch product. Figure 2An example of such a product is shown, illustrating an oral pouch product 200 comprising a cellulose sponge 202 treated with the oral composition described herein, the sponge being encapsulated in a woolen material 204. The term "woolen material" as used herein can be formed from various types of fibers capable of forming conventional woolen fabrics or other conventional pouch materials. For example, woolen materials can be provided in the form of woven or nonwoven fabrics. Suitable types of woolen materials are described, for example, in U.S. Patent No. 8,931,493 to Sebastian et al.; U.S. Patent Application Publication No. 2016 / 0000140 to Sebastian et al.; and U.S. Patent Application Publication No. 2016 / 0073689 to Sebastian et al., all of which are incorporated herein by reference. The term "nonwoven" is used herein to refer to fibrous materials, webs, pads, wadding, or sheets in which fibers are arranged in an undefined or random orientation. Nonwoven fibers initially exist as unbonded fibers or filaments. An important step in the manufacture of nonwoven fabrics involves bonding various fibers or filaments together. The way fibers or filaments are combined can vary and includes thermal, mechanical, and chemical techniques, some of which are selected based on the desired properties of the final product.
[0206] In some embodiments, the fibers within the wool fabric material may include, but are not limited to, polymers selected from the group consisting of: polyglycolic acid, polylactic acid, polyhydroxyalkanoates, polycaprolactone, polybutylene succinate, polybutylene adipate succinate, and copolymers thereof. In some embodiments, the fibers within the wool fabric material may be selected from the group consisting of: wool, cotton, fibers made from cellulose materials (such as regenerated cellulose, cellulose acetate, cellulose triacetate, cellulose nitrate, ethyl cellulose, cellulose acetate propionate, cellulose acetate butyrate, hydroxypropyl cellulose, methyl hydroxypropyl cellulose), protein fibers, etc. In some embodiments, the wool fabric material may include viscose fibers, including but not limited to viscose fibers derived from tobacco. The method of preparing regenerated cellulose is not limiting and may include, for example, both the rayon process and the TENCEL process. Various suppliers of regenerated cellulose are known, including Lenzing (Austria), Cordenka (Germany), Aditya Birla (India), and Daicel (Japan). In some embodiments, the wool fabric material is also biodegradable and / or compostable. In some embodiments, the basis weight of the wool fabric material can be from about 20 gsm to about 40 gsm, from about 30 gsm to about 40 gsm, or from about 25 gsm to about 30 gsm. In some embodiments, the thickness of the wool fabric material can be from about 0.1 mm to about 0.3 mm (e.g., from about 0.1 to about 0.2 mm, for example, about 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, or 0.18 mm).
[0207] Alternatively, the sponge material itself can be used as a pouch material, and any oral composition components described herein (such as fillers, active ingredients, flavoring agents) can be added to the cavity within the sponge.
[0208] Many modifications and other embodiments of this disclosure will arise to those skilled in the art upon having benefited from the teachings presented in the foregoing description. Therefore, it should be understood that this disclosure is not limited to the specific embodiments disclosed, and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terminology is used herein, it is used only in a general and descriptive sense and not for limiting purposes.
Claims
1. An oral product suitable for oral administration, comprising: A porous sponge that carries an oral composition that can be released in the oral cavity.
2. The oral product of claim 1, wherein the porous sponge comprises a cellulose material, such as a regenerated cellulose material.
3. The oral product of claim 1, wherein the oral composition comprises at least one water-soluble component, such as at least one active ingredient, at least one flavoring agent, or a combination thereof.
4. The oral product of claim 1, wherein the oral composition comprises one or more active ingredients selected from the group consisting of: nutritional supplements, plant materials, amino acids, vitamins, minerals, terpenes, and combinations thereof.
5. The oral product of claim 1, wherein the oral composition comprises a nicotine component selected from nicotine free bases, nicotine salts, nicotine polymer complexes, or combinations thereof.
6. The oral product of claim 5, wherein the oral composition comprises nicotine in an amount of about 0.001% to about 10% by weight of the composition, calculated as free base and based on the total weight of the composition.
7. The oral product of claim 1, wherein the oral composition comprises one or more flavoring agents, one or more salts, one or more sweeteners, one or more binders, one or more humectants, one or more gums, tobacco materials, or combinations thereof.
8. The oral product of claim 1, wherein the oral composition is attached to the porous sponge by an adhesive component or absorbed / adsorbed within the porous sponge.
9. The oral product of claim 8, wherein the adhesive component is selected from povidone, alginate, pectin, gum, carrageenan, pullulan, zein, cellulose ether, starch, dextran, acrylic resin, or combinations thereof.
10. The oral product of claim 1, wherein the oral composition is in the form of one or more capsules, the capsules comprising an encapsulating agent encapsulating the at least one active ingredient, at least one flavoring agent, or a combination thereof.
11. The oral product of claim 10, wherein one or more capsules comprise a plurality of microcapsules.
12. The oral product of claim 1, wherein the oral product exhibits biodegradability according to one or more of ASTM D5338, ASTM D5511, ASTM D5526, D5988, ASTM D6400 and ASTM D6691.
13. The oral product of claim 1, wherein the porous sponge is characterized by one or more of the following: i) Density is between approximately 20 and approximately 60 kg / m³ 3 Within the range; ii) Its water absorption capacity is approximately 10 to 20 times the dry weight of a porous sponge; and iii) The pore size ranges from about 4 nm to about 1000 micrometers, for example, from about 1 to about 500 micrometers or from about 1 to about 100 micrometers.
14. A method for preparing an oral product, comprising: Provide porous sponges; and A porous sponge is treated with an oral composition that can be released into the oral cavity, the oral composition comprising at least one active ingredient, at least one flavoring agent, or a combination thereof.
15. The method of claim 14, wherein the treatment comprises spraying the oral composition onto a porous sponge, immersing the porous sponge in the oral composition, or injecting the oral composition into the porous sponge.
16. The method of claim 14, wherein the treatment comprises treating a porous sponge with a plurality of microcapsules comprising an oral composition.
17. The method of claim 16, further comprising treating the plurality of microcapsules with an adhesive component prior to treating the porous sponge with the plurality of microcapsules.
18. The method of claim 14, further comprising treating the porous sponge with an adhesive composition prior to treating the porous cellulose sponge with the oral composition.
19. The method of claim 14, wherein the porous sponge comprises a cellulose material, such as a regenerated cellulose material.
Citation Information
Patent Citations
Process of bleaching tobacco-leaves.
US1086306A
Method and device for flavoring smokeless tobacco
US11246334B2
Process of bleaching tobacco
US1437095A
Process and device for ozonizing tobacco
US1757477A
Physically and chemically stable nicotine-containing particulate material
US20040191322A1
